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miRNAs are small, single stranded, non-coding RNAs that regulate gene expression at a 
post-transcriptional level. They are known to be involved in several biological processes 
and diseases such as cancer. Indeed, their abnormal expression alters the regulation of 
various cancer-related genes. 
The role of miRNAs in leukemia has been thoroughly studied but the function of 
specific miRNAs in the pathogenesis of the disease is not fully understood. The work 
performed in this thesis aimed at further understanding the role of some miRNAs in 
leukemia. The specific aims were: i) further understand the role of miR-21 in chronic 
myeloid leukemia (CML) cell lines; ii) investigate if miR-21 is present in various 
extracellular vesicles from CML cells and iii) study the role of miR-128 in an acute myeloid 
leukemia (AML) cell line. 
The overexpression of miR-21 has been observed in many cancers, including leukemia. 
The involvement of this miRNA in cancer related processes, such as chemoresistance, has 
been shown but its correlation with autophagy had never been addressed. In this thesis it 
is shown that by downregulating mR-21 expression with antimiRs, in K562 (CML) cells, 
there was a decrease in cellular viability and a decrease in cellular proliferation. miR-21 
downregulation also caused increased programmed cell death and a decrease in the 
expression levels of Bcl-2 protein, although PARP cleavage was not observed. Thus, the 
possible involvement of autophagy was analysed. It was verified that miR-21 
downregulation increased the expression of the autophagy related proteins Beclin-1, 
Vps34 and LC3-II.  Accordingly, an increase in autophagic vacuoles was seen, both by 
monodansylcadaverine and acridine orange staining as well as by transmission electron 
microscopy. In addition, downregulation of miR-21 expression increased the sensitivity of 
both K562 and KYO-1 (CML) cells to etoposide and doxorubicin, which was reverted by 
pre-treating cells with an autophagy inhibitor, 3-MA. Therefore, these results described 
for the first time autophagy induction via miR-21 downregulation and its involvement in 
drug sensitivity. 
Extracellular vesicles (EVs) have recently emerged as important intermediates of 
intercellular communication. These EVs, shed by donor cells, may contain proteins and 
both coding and non-coding RNAs, which can be transferred to recipient cells. In 
particular, it has become evident that EVs may carry miRNAs that are responsible for drug 




transported in EVs “shed” by CML cells, and moreover if different types of EVs carry 
different levels of miR-21. Indeed, there are various types of EVs, such as exosomes and 
microvesicles, but their isolation is still a technical problem. In this thesis, different EVs 
isolation protocols from K562 cells were employed, providing different EVs populations. 
This study showed that miR-21 was found in all extracted EVs and that its levels were not 
dependent on the type (size) of EVs isolated, suggesting that miR-21 is not specifically 
“packaged” into a particular type of EVs. 
Another miRNA known to be involved in leukemia is miR-128. This miRNA has been 
described, together with other miRNAs, to allow the discrimination between acute 
myeloid leukemia (AML) and acute lymphoblastic leukemia. Moreover, miR-128 is 
included in miRNA signatures which allowed the characterization of a particular subtype 
of AML as well as being associated with worse clinical outcome in a subgroup of patients 
with high-risk molecular features of AML. However, no functional studies have been 
performed regarding miR-128 and leukemia. In this thesis, miR-128 overexpression was 
performed with miR-mimics in an AML cell line (HL-60). This overexpression resulted in 
decreased cellular viability and increased sensitization to chemotherapeutic agents, 
etoposide and doxorubicin. miR-128 overexpression also increased programmed cell 
death but did not affect cell cycle,  apoptosis or autophagy. In addition, increased DNA 
damage was observed upon miR-128 overexpression, which was confirmed by an increase 
in the comet’s tail intensity in the comet assay, an increase in the number of DNA repair 
foci stained with either γ-H2AX or 53BP1, as well as an increase in the levels of these 
proteins. These results showed for the first time an association of miR-128 with DNA 
damage in the leukemia context. 
Overall, the work presented in this thesis provided more insight into the role of 














miRNAs são pequenos RNAs não codificantes, de cadeia simples, que regulam a 
expressão génica a um nível pós-transcricional. É reconhecido o seu envolvimento em 
vários processos biológicos bem como em doenças como por exemplo o cancro. De facto, a 
sua expressão anormal altera a regulação de vários genes relacionados com o cancro. 
O papel dos miRNAs na leucemia foi já bastante estudado mas a função específica de 
alguns miRNAs na patogénese da doença ainda não é completamente compreendida. O 
trabalho apresentado nesta tese teve como objectivo compreender melhor o papel de 
alguns miRNAs na leucemia. Os objectivos específicos foram: i) compreender o papel do 
miR-21 em linhas celulares de leucemia mielóide crónica (LMC); ii) investigar se o miR-21 
está presente em várias vesículas extracelulares de células de LMC e iii) estudar o papel do 
miR-128 numa linha celular de leucemia mielóide aguda (LMA). 
A sobre-expressão do miR-21 foi já descrita em vários cancros incluindo na leucemia. O 
envolvimento deste miRNA em processos relacionados com o cancro, tal como a 
resistência a fármacos antineoplásicos, foi já demonstrado mas a sua correlação com 
autofagia nunca foi investigada. Nesta tese, demonstra-se que por diminuição da 
expressão do miR-21, com antimiRs, na linha celular K562 (de LMC), ocorreu uma 
diminuição da viabilidade celular assim como uma diminuição da proliferação celular. A 
diminuição de expressão do miR-21 também causou um aumento da morte celular 
programada e uma diminuição dos níveis de expressão da proteína Bcl-2, embora não se 
tenha observado clivagem da proteín PARP. Assim, o possível envolvimento de autofagia 
foi analisado. Verificou-se que a diminuição de expressão de miR-21 aumentou a 
expressão de proteínas relacionadas com a autofagia: Beclina-1, Vps-34 e LC3-II. Em 
concordância, foi também observado um aumento de vacúolos autofágicos, por marcação 
com monodansilcadaverina ou com laranja da acridina, bem como por microscopia 
electrónica de transmissão. Para além disso, a diminuição de expressão do miR-21 
aumentou a sensibilidade das linhas celulares K562 e KYO-1 (de LMC) ao etoposídeo e 
doxorrubicina, sensibilidade esta que foi revertida com pré-tratamento das células com 
um inibidor de autofagia, 3-MA. Assim, estes resultados descrevem, pela primeira vez, a 
indução de autofagia através da diminuição da expressão do miR-21, bem como o 
envolvimento dessa autofagia na sensibilidade a fármacos. 
As vesículas extracelulares (VEs) apareceram recentemente como importantes 
mediadores da comunicação intercelular. Estas VEs, libertadas por célula dadoras, podem 




células receptoras. Em particular, tornou-se evidente que as VEs podem transportar 
miRNAs que são responsáveis pela resistência a fármacos, transferidos de células 
resistentes para células sensíveis. No entanto, não se sabe se o miR-21 é transportado em 
EVs libertadas por células de LMC, e além disso, se diferentes tipos de EVs transportam 
diferentes níveis de miR-21. De facto, existem vários tipos de EVs, como exossomas e 
microvesículas, mas o seu isolamento ainda se debate com problemas técnicos. Nesta tese, 
diferentes protocolos de isolamento EVs a partir de células K562 foram usados, 
originando diferentes populações de EVs. Este estudo mostrou que o miR-21 foi 
encontrado em todos as VEs extraídas e que os seus níveis não são dependemtes do tipo 
(tamanho) das VEs isoladas, sugerindo que o miR-21 não é ‘empacotado’ de forma 
específica num determinado tipo de VEs.  
Outro miRNA que está envolvido em leucemia é o miR-128. Este miRNA foi descrito, 
juntamente com outros miRNAs, como permitindo a discriminação entre LMA e leucemia 
linfoblástica aguda. Para além disso, o miR-128 está também incluído em assinaturas de 
miRNAs que permitem a caracterização de sub-tipos de LMA, bem como associado com 
pior evolução clínica num subgrupo de doentes com características moleculares de LMA 
de alto risco. Contudo, não existem estudos funcionais realizados com miR-128 em 
leucemia. Nesta tese, a sobre-expressão de miR-128 foi conseguida com mímicos de 
miRNAs numa linha celular de LMA (HL-60). Esta sobre-expressão resultou numa 
diminuição da viabilidade celular e aumento da sensibilidade a dois agentes 
antineoplásicos: etoposídeo e doxorrubicina. A sobre-expressão de miR-128 também 
aumentou os níveis de morte celular programada sem, no entanto, afetar o ciclo celular, 
apoptose ou autofagia. Para além disso, observou-se um aumento nos danos do DNA após 
sobre-expressão do miR-128, que foi confirmado por um aumento na intensidade da 
cauda dos cometas no ‘ensaio de cometas’, por um aumento do número de focos de 
reparação de DNA, marcados com H2AX ou 53BP1 e por um aumento dos níveis de 
expressão destas mesmas proteínas. Estes resultados mostram, pela primeira vez, uma 
associação do miR-128 com danos no DNA, em leucemia. 
De um modo geral, o trabalho apresentado nesta tese proporcionou mais conhecimento 
sobre o papel dos miRNAs na resposta a fármacos citotóxicos na leucemia, contribuindo 
para o conhecimento global neste domínio. 
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1.1  ACUTE MYELOID LEUKEMIA  
Acute myeloid leukemia (AML) is a genetically pleomorphic disease characterized by a 
clonal disorder of hematopoietic stem cells that disturb normal mechanisms of self-
renewal, proliferation and differentiation. Therefore, there is a subsequent accumulation 
of cells at different stages of inadequate maturation as well as reduction of healthy 
hematopoietic cells (reviewed in Dohner and Gaidzik 2011; Estey and Dohner 2006; 
Schlenk et al. 2008; reviewed in Garzon et al. 2008b). AML is defined by a rapid disease 
tempo which progresses over weeks to months and is classified as a biologically 
heterogeneous disease with distinct clinical presentations in different morphological and 
cytogenetic subtypes.  
AML has traditionally been classified based on morphologic characteristics, 
immunohistochemistry and immunophenotyping according to the French–American–
British (FAB) classification. More recently, cytogenetic and molecular diagnostic analyses 
have been added as a complement for a better classification of AML (reviewed in 
Vardiman et al. 2009). The new classification of hematological malignancies published by 
the World Health Organization in 2008 (Swerdlow et al. 2008) defines 108 new diagnostic 
entities in hematopathology, including 50 new or provisional leukemia entries (reviewed 
in Betz and Hess 2010). AML diagnosis starts with morphologic examination to confirm 
the presence of at least 20% blasts in bone marrow or blood and its characterization is 
followed by cytogenetical analysis. Between 50 and 60% of AMLs present cytogenetical 
alterations with around 45% having an abnormal karyotype with a recurrent chromosomal 
alteration, and about 15% presenting 3 or more cytogenetic alterations (complex 
karyotype) (reviewed in Mrozek et al. 2004). Prognosis and genetics of AML are tightly 
linked. Risk stratification based on cytogenetics divides patients into three main groups, 
those with favorable, intermediate, and unfavorable cytogenetics (Table 1). Favorable 
prognosis subtypes include acute promyelocytic leukemia (associated with the 
translocation t(15;17)) and the core binding factor (CBF) leukemias (that include the 
translocations t(8;21)(q22;q22) and t(16;16)(p13.1;q22) and the inversion 
inv(16)(p13.1;q22)). An intermediate prognosis group includes the translocation 
t(9;11)(p22;q23) and trisomy of chromosome 8. A third group with adverse prognosis 
encompasses complex karyotypes, translocations t(3;3)(q21;q26.2) or t(6;9)(q23;q34), 
inversion inv(3)(q21;q26.2), deletion of chromosomes 5 or 7 or abnormalities of 17p as 
well as abnormalities of 11q23 (reviewed in Brown et al. 2012). 
 






















Adapted from (Dohner et al. 2010; Brown et al. 2012) 
 
Monosomal karyotypes (two or more autosomal monosomies or one autosomal 
monosomy with at least one other structural abnormality) are a particular bad prognosis 
group (Breems et al. 2008). Besides the cytogenetic alterations, there are many patients 
that do not present any detectable chromosomal alteration – cytogenetically normal (CN) 
– but who harbor mutations or altered expression of specific genes and they represent 
about 40-50% of AML patients being the largest subset of AML (reviewed in Mrozek and 
Bloomfield 2006). Mutations in NPM1, CEBPA and FLT3-ITD have allowed stratifying 
patients in terms of prognosis (Table 1). For example, NPM1 or biallelic CEBPA mutations 
confer a favorable prognosis (similar to the favorable group defined by karyotype) and 
patients harboring FLT3-ITD mutations have a worse prognosis (Schlenk et al. 2008). 
There are other molecular alterations that can be found in AML including mutations in c-
KIT, IDH1, IDH2, WT1, RUNX1, TET2 and DNMT3A but they still do not present a 
prognostic value (Patel et al. 2012). 
Risk profile Risk stratification 
 Cytogenetic 
Molecular genetic 
abnormalities that further 
stratify CN-AML 
Favorable acute promyelocytic leukemia t(15;17)  
t(8;21)(q22;q22) NPM1 mutation (without  
t(16;16)(p13.1;q22) FLT3-ITD mutation) 
inv(16)(p13.1q22) biallelic CEBPA mutation 
Intermediate normal karyotype  
t(9;11)(p22;q23)   
trisomy 8  




-5 or del(5q)  
-7  
abnormalities of 17p  
abnormalities of 11q23  






Nowadays, more than 90% of AML patients can be categorized on the basis of either 
cytogenetic (chromosomal banding technique and fluorescence in situ hybridization - 
FISH) or molecular genetic characteristics (reviewed in Seca et al. 2010). 
 
1.2  CHRONIC MYELOID LEUKEMIA 
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the 
neoplastic transformation of hematopoietic stem cells (reviewed in Ren 2005).  It is 
normally divided in two distinct phases: i) a benign, chronic phase, which median 
duration is 3-4 years, that is characterized by the expansion and accumulation of 
functionally normal myeloid precursors and mature cells that leave the bone marrow;  ii) 
an accelerated blastic phase where CML progenitor cells lose their capacity to 
differentiate, leading to a rapid expansion of myeloid or lymphoid blast cells in peripheral 
blood or bone marrow (reviewed in O'Hare et al. 2012; reviewed in Ren 2005). 
The majority of CML cases (95%) is characterized, molecular and cytogenetically, by the 
occurrence of an aberrant chromosome, named Philadelphia (Ph) chromosome (Figure 1). 
 
Figure 1. Philadelphia chromosome - 
banded chromosomes 9 and 22 show the 
result of the reciprocal translocation of 22q 
to the lower arm of chromosome 9 and 9q 
to the lower arm of chromosome 22 
(arrows indicate breakpoint regions). 
Adapted from  
http://www.nature.com/scitable/content/t
he-philadelphia-chromosome-25070: 
accessed in 26Oct2013) 
 
 
This chromosome is the consequence of a reciprocal translocation between the Abelson 
murine leukemia (ABL) gene on chromosome 9 and the breakpoint cluster region (BCR) 
gene on chromosome 22, resulting in the fusion gene BCR-ABL (reviewed in Jabbour and 
Kantarjian 2012). Depending on the place of break in the BCR gene there could be 
different chimeric proteins with variable size and molecular weight (reviewed in Faderl et 
al. 1999). These different proteins are related with phenotypic differences of the disease 
(reviewed in Kurzrock et al. 2003). In fact, BCR-ABL protein expression is responsible for 
the phenotypic abnormalities observed in the chronic phase of CML and is both crucial 
and sufficient for the malignant transformation of CML (Salesse and Verfaillie 2002; 
reviewed in Daley et al. 1990). BCR-ABL chimeric protein has constitutively tyrosine-
kinase activity (Ben-Neriah et al. 1986) which, considering its cytoplasmic localization 




(Wetzler et al. 1993), allows access to cellular substrates that promote growth and 
replication through the activation of pathways such as RAS, JUN kinase, MYC and STAT 
(Sawyers et al. 1992; Raitano et al. 1995; Mandanas et al. 1993; Ilaria and Van Etten 1996; 
Carlesso et al. 1996). The consequence of this downstream activation is cell proliferation 
independent of growth factors associated with an increase in apoptosis resistance 
(reviewed in Shet et al. 2002; reviewed in Calabretta and Perrotti 2004). BCR-ABL 
expression has been shown to exert dose-dependent effects on growth factor dependence, 
clonogenicity and migration (Barnes et al. 2005; Melo and Barnes 2007) as well as disease 
progression (Gaiger et al. 1995; Elmaagacli et al. 2000). 
 
1.3  RESPONSE TO THERAPY 
Leukemias are characterized by clonal expansion of bone marrow hematopoietic cells with 
increased blasts and aggressive clinical course. 
Hematologic malignancies are, most often, currently treated with non-targeted, highly 
cytotoxic drugs, radiation and/or bone marrow transplantation. 
There are few small molecule inhibitors and specific monoclonal antibodies that have been 
shown to significantly improve the patient clinical situation. Among these are small 
molecule inhibitors of BCR-ABL kinase activity for the treatment of BCR-ABL positive 
leukemias (Hughes et al. 2010; Druker et al. 2001) (Figure 2) and all-trans retinoic acid 
(ATRA) for the treatment of acute promyelocytic leukemia (APL) that express the fusion 
protein PML-RARα (reviewed in Sanz et al. 2009). 
However, even with the identification of the oncogenic driving force, the results achieved 
with these therapies are regularly insufficient to completely eradicate tumor cells and 
eventually the malignancy relapses. 
BCR-ABL tyrosine kinase inhibitors, led by imatinib, have completely changed the 
treatment of CML being able to sustain the disease in its chronic phase. Nevertheless, 
most patients will require lifetime treatment, as leukemic stem cells will persevere (Corbin 
et al. 2011; Hurtz et al. 2011). Moreover, advanced BCR-ABL positive leukemias show mild 
responses to BCR-ABL inhibitors with relapse occurring even if therapy is maintained 
(Foa et al. 2011). There is, however, a small subset of patients who reach complete 
molecular response (CMR) after treatment with imatinib and are able to maintain this 
CMR even after stopping treatment, suggesting that imatinib can ‘cure’ a small amount of 

























Figure 2.  Mechanism of action of the BCR-ABL tyrosine kinase and its 
inhibition by imatinib - When imatinib is in the kinase pocket (Panel B), the action 
of BCR-ABL is inhibited, by preventing phosphorylation of its substrates. Adapted 
from (Savage and Antman 2002) 
 
Contrary to CML, AML does not have a targeted therapy that treats most of the patients 
and several therapy methods have been employed in the treatment of this leukemia, such 
as radiotherapy, chemotherapy, immunotherapy, and bone marrow transplant. Although 
bone marrow transplant is considered an important therapeutic weapon to achieve 
complete remission, there are a lot of clinical restrictions to this procedure as well as to 
finding suitable donors. Chemotherapy using daunorubicin and cytarabine has been, for 
over three decades, the standard treatment for AML (reviewed in Burnett 2012). The rates 
of remission with standard induction chemotherapy, in patients with AML, vary between 
50% and 85% (Farag et al. 2005). However, the majority of patients will relapse and die of 
the disease within 2 years of accomplishing a remission. Remission rates and overall 
survival are dependent on several characteristics such as age of patient, cytogenetic 
alterations, other molecular changes or comorbid illness (reviewed in Shipley and Butera 
2009). 
Age and cytogenetics are closely related in AML. Adverse cytogenetic alterations increase 
with increasing age as the percentage of favorable cytogenetics drops from 17% in patients 
aged younger than 56 years to 4% in those aged older than 75 years. Moreover, the 
percentage of patients with unfavorable cytogenetics increases from 35% in those younger 
than 56 years to 51% in patients older than 75 years (Farag et al. 2005; Cancer et al. 2006). 
Both CML and AML patients, despite the better overall survival that new treatments have 
provided, relapse due to drug resistance which can be classified as intrinsic or extrinsic 
(reviewed in Stegmeier et al. 2010; reviewed in Fojo 2007).  




Intrinsic resistance is associated with an innate property of the cancer cells that prevents 
an optimal response to therapy, while extrinsic (or acquired) resistance refers to a 
characteristic gained (or selected for) during therapy and leads to the loss of clinical 
response. The mechanisms of intrinsic resistance encompass those that mediate cell 
quiescence (Kumari et al. 2012; Graham et al. 2002), downregulation of pro-apoptotic 
molecules (San Jose-Eneriz et al. 2009a), overexpression of anti-apoptotic molecules 
(Konopleva et al. 2006; Kohl et al. 2007) or promotion of autophagy (Bellodi et al. 2009). 
Extrinsic resistance mechanisms have been associated with mutations or amplification of 
the gene that encodes for the protein that is targeted by the selected therapy, amplification 
of other genes that lead to the triggering of alternative or redundant pathways in the cell 
and increased expression of cellular energy-dependent drug transporters (efflux pumps) 
(le Coutre et al. 2000; Thomas et al. 2004; Aceves-Luquero et al. 2009). Mutations in the 
tyrosine kinase domain (TKD) of BCR-ABL are a good example of acquired resistance as 
they have been shown to thwart drug binding (Gorre et al. 2001; Sherbenou et al. 2010). 
Similar mechanisms of acquired resistance to FLT3 inhibitors involve mutations in the 
TKD of FLT3 and have been described in AML (Moore et al. 2012; Bagrintseva et al. 
2004). The most common cause of acquired drug resistance is the cellular expression of 
drug efflux pumps, a superfamily of transport proteins called ATP-binding cassette, which 
transfer anticancer drugs from the inside to the outside of the cell. Alterations in the 
expression of these drug efflux pumps have been shown to occur both in AML and CML 
(reviewed in Mahon et al. 2008; Mahadevan and List 2004). Since efflux pumps are not 
substrate specific, cells overexpressing these pumps, such as the P-glycoprotein (P-gp), are 
multidrug-resistant, defining a phenotype known as multidrug resistance (MDR) 
(reviewed in Gottesman et al. 2002). 
Intra-tumoral genetic heterogeneity, with multiple clones within the same tumor showing 
different kinds of aggressiveness (Gerlinger et al. 2012) or sub-clones of the same tumor 
displaying amplification of three different receptor tyrosine kinases in a mutually 
exclusive fashion (Snuderl et al. 2011), is another feature, likely present in almost all 
tumor types, that may represent a major obstacle for targeted therapeutic strategies being 













A broad variety of RNAs expressed in the genome have assorted functions, other than 
being only the “messengers” from DNA to protein expression. These RNAs, named non-
coding RNAs (ncRNAs), include an increasing amount of transcripts previously assumed 
to be “trash” but that are now starting to be classified and thoroughly studied. Among 
these ncRNAs, microRNAs (miRNAs or miRs) have excelled. miRNAs were first described 
in 1993, in two papers published in Cell, where lin-4, the first miRNA, was identified in a 
genetic screen for defects controlling the developmental timing of C. elegans, and it was 
shown to target lin-14 mRNA (Lee et al. 1993; Wightman et al. 1993). By then, genetic 
screens used to end up with protein-coding genes as these were the most obvious and 
functional targets, but the ncRNA lin-4 showed intriguing characteristics. It was a small 
~22-nt RNA that repressed the expression of the lin-14 gene by multiple imperfect pairing 
in the 3’UTR of lin-14 messenger RNA (mRNA). However, it took 8 years for ‘microRNA 
era’ to develop with dozens of miRNAs described in C. elegans, Drosophila and humans 
(Lee and Ambros 2001; Lau et al. 2001; Lagos-Quintana et al. 2001). Nowadays the 
miRNA database (http://www.mirbase.org/) already has over 24000 entries for a variety 
of species and over 2500 mature sequences for humans. 
miRNAs are a class of single-stranded ncRNAs that range from 19 to 25 nucleotides in 
length and have significant roles in gene regulation (reviewed in Bartel 2004). In humans, 
miRNAs represent 1-4% of the genome and are spread through its entire length besides 
the Y chromosome with about half of the miRNAs situated in intergenic regions while the 
other half can be found within coding genes (Rodriguez et al. 2004; Saini et al. 
2008).Taking into consideration their location in the genome, miRNAs can be classified in 
four different categories: i) intronic miRNAs in non-coding transcripts, such as the miR-
15a~16-1 cluster found in the intron of a well-defined ncRNA gene, DLEU2 (Calin et al. 
2002); ii) exonic miRNAs in non-coding transcripts, such as miR-155 which was found in 
the ncRNA gene, BIC (Tam 2001); iii) intronic miRNAs in protein-coding transcripts, such 
as the miR-25~93~106b cluster, which is embedded in the intron of the DNA replication 
licensing factor MCM7 transcript (Kim and Kim 2007); iv) exonic miRNAs in protein-
coding transcripts, like miR-985 which is found in the last exon of CACNG8 mRNA (Kim 
and Kim 2007). With about 40% of all miR loci found in intronic regions of protein-coding 
transcripts it would be expectable that those miRNAs shared common promoters and were 
expressed together with their host genes (Baskerville and Bartel 2005; Wang et al. 2009). 
However, there are some studies reporting that co-expression of miRNAs and host genes 
is rare or happens only in a cell/tissue specific context (Biasiolo et al. 2011; He et al. 2012). 




2.1 MIRNAS BIOGENESIS 
The miRNAs have a standard biogenesis that comprises three major phases: 1) 
transcription; 2) maturation and 3) assembly (reviewed in Winter et al. 2009) (Figure 3). 
This canonical biogenesis of miRNAs starts in the nucleus with the transcription of long 


















Figure 3. The miRNA biogenesis process. 
 
These pri-miRs are characterized by a stem-loop structure and have some common 
features with mRNAs such as 5’cap and 3’poly adenylation (Cai et al. 2004). While still in 
the nucleus, pri-miR is cropped to precursor microRNA (pre-miR), a 70-100 nucleotides 
hairpin structure, by an RNase III enzyme, Drosha, and its interacting partner DGCR8 
(Lee et al. 2003; Denli et al. 2004). Some miRNAs, namely miRtrons, bypass the Drosha-
mediated cleavage with miRs being generated as by-products of splicing events (Ruby et 
al. 2007). The next processing step occurs in the cytoplasm, following the transport of pre-
miR from the nucleus to the cytoplasm by exportin-5 (Lund et al. 2004). In the cytoplasm, 
pre-miR is thereafter converted to a miRNA duplex by another RNase III enzyme – Dicer 
(Hutvagner et al. 2001) and its partner TRBP, an essential RNA binding protein 
(Chendrimada et al. 2005). Following Dicer/TRBP processing, the double stranded 





strand (~22nt) is loaded together with Argonaute (Ago) protein into the RNA-induced 
silencing complex (RISC), the passenger strand is degraded (Gregory et al. 2005). The 
mature strand is thought to be the one whose 5’ end is thermodynamically more unstable, 
thus becoming more easily unwounded by the helicase (Schwarz et al. 2003; Khvorova et 
al. 2003). Association of miRNA loaded RISC with mRNAs through partial or full 
complementarity to its 3’-UTR region leads to post-transcriptional suppression of the 
target mRNA expression: if there is full complementarity between miRNA and mRNA, 
mRNA cleavage occurs, while partial complementarity causes translational repression 
(reviewed in Filipowicz et al. 2008; reviewed in Valencia-Sanchez et al. 2006; reviewed in 
Liu 2008). mRNAs have been shown to accumulate and/or be degraded in P-bodies 
(cellular structures that are enriched in mRNA-catabolizing enzymes and translational 
repressors) (Parker and Sheth 2007; reviewed in Liu et al. 2005). 
 
2.2 REGULATION OF GENE EXPRESSION BY MIRNAS 
The pairing of miRNA with its target mRNA occurs mainly through the binding of the 
miRNA to the mRNA 3’-UTR. Nevertheless, binding to the coding region or to the 5’UTR 
may also occur (Orom et al. 2008). One mRNA may have numerous binding sites for the 
same miRNA or enclose binding sites for different miRNAs (Brodersen and Voinnet 2009; 
reviewed in John et al. 2004). This promotes the opportunity for various miRNAs binding 
the same mRNA and thereby regulating cooperatively the expression of a single mRNA, 
singling the complex system that underlies miRNA regulation of mRNA expression 
(reviewed in Berezikov 2011; reviewed in Winter et al. 2009; reviewed in He and Hannon 
2004). Moreover, some miRNAs regulate specific individual targets while others regulate 
the expression of several genes simultaneously. 
In addition to their canonical function, as inhibitors of mRNA expression, miRNAs can 
exert a non-canonical function as positive regulators of gene expression (Place et al. 2008; 
Dong et al. 2011; Vasudevan et al. 2007), by binding to protein-coding exons (reviewed in 
Rigoutsos 2009) or promoters (Orom et al. 2008; Piriyapongsa et al. 2012). 
Recognition of a target mRNA by a miRNA is mainly done by the first 2-7 nucleotides 
which are situated in the 5’end of the mature miRNA, known as the “seed” sequence 
(Lewis et al. 2003). Besides the perfect match between the “seed” sequence of a miRNA 
and its target mRNA, other features of site context may boost the efficacy of miRNA-
mRNA interaction (Shin et al. 2010; Grimson et al. 2007). The complexity of the 
interaction between miRNAs and their target mRNAs may be better understood with the 
help of bioinformatics. Indeed, there are currently a great number of bioinformatic tools 
such as TargetScan, miRanda, PICTAR, Diana-microT, miRWalk which have been 




developed to predict the target sites of miRNAs in silico (Dweep et al. 2011; Min and Yoon 
2010). Their algorithms are mainly based on base pairing interactions between miRNAs 
and their target mRNAs. Still, their output data varies, making biological validation 
unavoidable and essential to understand their targets and functional roles in the cell. To 
confirm if a predicted target is indeed a real target, an assay involving a luciferase reporter 
is used as the gold standard reporter assay. This assay consists in verifying if the wild-type 
3’-UTR of a predicted target is repressed by an overexpressed miRNA and if the inclusion 
of a point mutation in the target sequences of the 3’-UTR abrogates this repression; if 
those two situations happen, then the studied mRNA is considered a target of that specific 
miRNA. 
As miRNA-mediated regulation controls the expression of a wide amount of different 
mRNAs involved in multiple key cellular processes (Fu et al. 2012; Lima et al. 2011; Li and 
He 2012; Bueno and Malumbres 2011; Bueno et al. 2008b), their biogenesis and relative 
abundance must also be regulated in a tight manner, especially in what concerns their 
transcription, processing and cellular localization levels (reviewed in Slezak-Prochazka et 
al. 2010; Davis-Dusenbery and Hata 2010; reviewed in Melo et al. 2010). Transcription 
factors, enhancers and chromatin modifications may alter miRNA expression levels, either 
positively or negatively (Ozsolak et al. 2008; Wang et al. 2010a). Recently, miRNAs have 
been shown to be included into extracellular vesicles therefore targeting neighboring cells 
(Yang et al. 2011; Umezu et al. 2012), as well as to enter the blood stream therefore 
reaching distant cells (Ogawa et al. 2010; Zhang et al. 2010). 
Ultimately, by being expressed in the entire organism and interfering in most of the 
cellular mechanisms, miRNAs ‘control’ the cellular phenotype in processes such as 
development (reviewed in Amiel et al. 2012) and differentiation (reviewed in Hinton et al. 
2012). Moreover, their aberrant expression is often associated with a wide variety of 
illnesses broadening from diabetes (reviewed in Natarajan et al. 2012), to cardiovascular 
disease (reviewed in van Rooij and Olson 2012) or to various types of cancers (reviewed in 
Liu 2012; reviewed in Singh et al. 2012; reviewed in Schetter et al. 2012; reviewed in Seca 
et al. 2010). 
 
2.3 MIRNAS AND CANCER 
miRNAs were first linked with cancer in 2002, when miR-15a and miR-16-1 were 
associated with chronic lymphocytic leukemia (Calin et al. 2002). This discovery was the 
trigger for the investigation of the chromosomal location of miRNAs as well as for the 
study of the profile of miRNAs expression in various human cancers. Interestingly, 





regions of loss of heterozygosity, minimal regions of amplification or common breakpoint 
regions (Calin et al. 2004). Expression profiles of miRNAs showed an altered expression 
of miRNAs in tumors when compared to normal tissue (Calin and Croce 2006; reviewed in 
Lu et al. 2005; Volinia et al. 2006) with miRNAs being able to accurately classify different 
tumour types as well as poorly differentiated tumours and trace the tissue of origin of 
cancers of unknown primary origin (Lu et al. 2005; Rosenfeld et al. 2008). 
Besides the relevant information that aberrant expression profiles of miRNAs provides, 
understanding the mechanisms and biological alterations that underlie such deregulations 
is also very important. Transcriptional deregulations, epigenetic alterations, mutations, 
DNA copy number abnormalities and defects in the miRNA biogenesis machinery have 
been shown to contribute to miRNA deregulation in human cancer (reviewed in Deng et 
al. 2008; reviewed in Iorio and Croce 2012). This deregulation, depending on their target 
mRNAs, prompts miRNAs to act as tumor suppressors (named “tumor suppressor 
miRNAs”) or oncogenes (named “oncomirs”) (reviewed in Esquela-Kerscher and Slack 
2006). Therefore, miRNAs whose expression is decreased in cancer, and normally target 
oncogenes, are “tumor suppressor miRNAs”. On the other hand, miRNAs whose 
expression is increased in cancer and confers them an oncogenic role, usually targeting 
tumor suppressor genes, are “oncomirs” (reviewed in Zhang et al. 2007). However, this 
classification needs to be used with caution, as the same miRNA can function as an 
oncomir or a tumor suppressor miRNA depending on the cellular context/tissue (reviewed 
in Chen et al. 2012a). 
Abnormal miRNA expression can be regarded as a common feature of human cancers and 
therefore the involvement of miRNAs in cancer can be described by the role they play in 
the “hallmarks of cancer”: t sustaining proliferative signaling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing angiogenesis, and 
activating invasion and metastasis (reviewed in Hanahan and Weinberg 2011; reviewed in 
Ruan et al. 2009). 
 
2.4 MIRNAS AND POTENTIAL APPLICATIONS IN THE ONCOLOGY 
CLINIC 
Since cancer is one of the leading causes of death worldwide (reviewed in Jemal et al. 
2011) there is a need for better diagnostic tools as well as biomarkers for early detection. 
This is relevant since  the stage of the tumor at the time of diagnosis is related to survival 
and prognosis (with early detection normally being associated with better prognosis). 




MiRNAs may have potential useful clinical applications, since they:   i) are resistant to 
ribonuclease degradation; ii) can be accessible from small biopsies, frozen samples, 
formalin-fixed paraffin-embedded tissues and circulating blood,; iii) may be quantified 
with highly sensitive measurements (Xi et al. 2007).  
The fact that miRNAs are deregulated in cancer makes their expression pattern useful and 
ideal to be used as cancer biomarkers. In fact, miR-21 and miR-205 have been used for 
early detection of pancreatic ductal adenocarcinoma cancer, as their overexpression 
preceded phenotypic changes in the pancreas ducts (du Rieu et al. 2010). miRNAs have 
also been shown to be able to identify the tissue of origin of a tumor (Lu et al. 2005) as 
well as to separate different cancer types (Volinia et al. 2006) or discriminate different 
subtypes of breast cancer (Blenkiron et al. 2007). However, and despite their promising 
value, miRNA expression profiles of tumours are not yet used in the clinic. 
Another focus of current research is the study of circulating miRNAs in serum, plasma, 
peripheral blood mononuclear cells and other body fluids (reviewed in Cortez et al. 2011). 
The presence of miRNAs in body fluids may represent a gold mine of noninvasive 
biomarkers in cancer, as their circulating levels mimic the pattern of expression observed 
in the tumor (Lawrie et al. 2008). For example, let-7 expression could classify lung cancer 
samples from patients who underwent potentially curative resection into two major 
groups, with reduced let‑7 expression associated with significantly shorter survival after 
resection (Takamizawa et al. 2004). In a study of non-small-cell lung cancer, a set of 11 
serum miRNAs was differentially expressed between patients with longer or shorter 
survival, with four (miR‑486, miR‑30d, miR‑1, and miR‑499) associated with decreased 
overall survival of patients (Hu et al. 2010b). Moreover, in a study of acute leukemias, 
there was a decrease of miR-92a in the plasma samples of all patients compared with 
controls (Tanaka et al. 2009). 
The ability of miRNAs to predict the response to a particular therapy is also of great value 
to clinicians. Overexpression of miR-21 was associated with shorter overall survival of 
pancreatic cancer patients treated with gemcitabine (Giovannetti et al. 2010) while 
downregulation of miR-26, in hepatocellular carcinoma patients, led to a good response to 
interferon-α treatment, resulting in improved survival (Ji et al. 2009). 
Deregulation of miRNA expression is a common feature in cancer and their biological role 
has been established. Therefore, the usage of molecules that directly interfere with the 
amount of miRNAs in the cell, such as miR-mimics (that replace the loss of expression of a 
tumor suppressor miRNA) or antimiRs, antagomiRs or miR sponges (that decrease the 
endogenous highly expressed oncomir) would be of great interest as therapeutic tools. 
Drugs that modulate the expression of miRNAs by targeting their transcription and 





One example came from studies of downregulation of miR-122, an abundant liver-specific 
miRNA, after injection of antagomiRs (oligonucleotides chemically modified with 2´-O-
methyl and phosphorothioate) in the tail vein of mice, which was long lasting and efficient. 
This was the first successful report of miRNA targeting in vivo (Krutzfeldt et al. 2005). 
Indeed, since then, antimiR-122 has been developed for clinical use (hepatitis C) having so 
far reached phase II clinical trials (ClinicalTrials.gov Identifier: NCT01200420).  
The miRNA sponges are constructs that competitively inhibit endogenous miRNAs by 
presenting various binding sites for these miRNAs, thus decreasing their quantity (Ebert 
et al. 2007). miRNA sponges have been applied in functional studies, for example, to study 
miR-31 in metastasis (Valastyan et al. 2009). One advantage is that a unique miRNA 








































































3. MIRNAS AND AML 
3.1 MIRNA SIGNATURES IN AML  
Different studies have been published concerning miRNA profiling in different cancer 
types (reviewed in Bhatti et al. 2009; reviewed in Dillhoff et al. 2009), amongst which 
AML profiling has also been documented (Isken et al. 2008; Garzon et al. 2008b; Dixon-
McIver et al. 2008; Jongen-Lavrencic et al. 2008; Diaz-Beya et al. 2013). The first miRNA 
expression profile in AML (Mi et al. 2007) evaluated if miRNA signatures would 
discriminate between AML and acute lymphoblastic leukemia (ALL). Samples from 11 ALL 
patients, 47 AML patients (both with similar chromosomal translocations), as well as from 
7 cell lines of each malignancy were evaluated. 27 miRNAs were found differently 
expressed between ALL and AML. Of those, miR-128a, miR-128b, let-7b and miR-223 had 
significantly altered expression between ALL and AML. Using any two of these four 
miRNAs signatures was sufficient to accurately (97–99%) discriminate ALL from AML 
(Mi et al. 2007). A more recent study has addressed the same question: to find miRNAs 
differentially expressed between AML and ALL. Analysis of 23 miRNAs in 53 AML and 32 
ALL bone marrow samples showed that 16 miRNAs were differentially expressed between 
AML and ALL. Eight had already been reported (Mi et al. 2007) and the other eight were 
newly identified. Correlating miRNA expression signatures with outcome of patients 
showed that the expression signatures of a group of miRNAs were associated with overall 
survival of patients. Of them, three (miR-146a, miR-181a/c, and miR-221) and five (miR-
25, miR-26a, miR-29b, miR-146a, and miR-196b) miRNAs were significantly associated 
with overall survival of ALL and AML, respectively. Particularly, the expression signature 
of miR-146a was shown to be significantly inversely correlated with overall survival of 
both ALL and AML patients (Wang et al. 2010b). 
Comparison of 50 AML bone marrow samples with 7 normal bone marrow samples as well 
as 5 CD34+ blood samples was performed, by analysing 154 miRNAs. Four miRNAs were 
found differently expressed in AML (Isken et al. 2008). From those, miR-23b was 
downregulated and miR-34a, miR-221 and miR-222 were upregulated in AML samples 
when compared to controls. Three other miRNAs (miR-26a, miR-26b and miR-29b) were 
differentially expressed between the groups, with an intermediate expression level in 
AML, being highly expressed in normal bone marrow samples and having low expression 
in CD34+ cells, appearing to be related with differentiation. Indeed, these miRNAs were 
shown to be upregulated upon ATRA induced differentiation of HL-60 cells (Isken et al. 
2008). 




Another study comparing microRNA levels by microarray  between  newly diagnosed AML 
patients and CD34+ bone marrow cells from 10 normal donors identified 26 
downregulated miRNAs in AML (Garzon et al. 2008b). The results from 7 of the 
downregulated miRNAs (miR-93, miR-106b, miR-125a, miR-126, miR-130a, miR-135 and 
miR-146) were validated by quantitative RT-PCR. The results from the microarray 
analysis were further confirmed, in six more AML samples and four CD34+ blood 
samples, for all the miRNAs except miR-135. Of these miRNAs, miR-93, miR-125a, miR-
126, miR-130a and miR-146 were not only downregulated in AML samples, when 
compared with CD34+ cells, but also downregulated in healthy precursors and mature 
peripheral blood myeloid cells. These results indicate that the downregulation of these 
miRNAs is probably not directly related to disease but rather to differentiation (Garzon et 
al. 2008b). In a study performed in 100 AML patients (analysing 157 miRNAs), 
representative of the range of karyotypes known in AML (Dixon-McIver et al. 2008), 17 
upregulated and 16 downregulated miRNAs were found in AML when compared to bone 
marrow controls, with some of the upregulated miRNAs having been previously described 
as hematopoietic tissue-specific: miR-142-5p, miR-155 and miR-181 (Chen et al. 2004; 
Georgantas et al. 2007; Debernardi et al. 2007; reviewed in Seca et al. 2010). Additional 
miRNAs found upregulated in AML were miR-221 and miR-222, which was in agreement 
with other publications (Isken et al. 2008). Amongst the miRNAs found downregulated 
were some previously described as having anti-oncogenic potential in other cancers – 
miR-26a, miR-34c and miR-199a (Gaur et al. 2007; Corney et al. 2007; reviewed in Seca 
et al. 2010). 
Some of the studies reporting miRNA profiles took into account the diverse cytogenetic 
alterations present in AML patients. A study with 215 genetically defined de novo AML 
patients and four samples of CD34+ cells from healthy donors analysed 260 miRNAs. This 
study allowed to cluster together AMLs with t(8;21), t(15;17), inv(16), NPM1 or CEBPA 
mutations with an unsupervised clustering approach. By using a supervised analysis, 
miRNA signatures that could characterize cytogenetic abnormal AMLs – t(15;17), t(8;21) 
and inv(16) – were identified, as well as signatures that distinguished NPM1 mutations, 
CEBPA mutations or FLT3 internal tandem duplication (FLT3-ITD). This study showed 
that although miRNAs were able to distinguish different genetic AMLs, the mRNA 
expression profiling was more accurate in predicting the same AMLs and it required a 
smaller number of probes. Nonetheless, a very small number of miRNAs were studied 
when compared with the number of mRNAs analysed (260 miRNAs compared with 54675 
mRNAs),  indicating the potential of profiling miRNAs for the molecular diagnosis of AML  





Two studies have concentrated on AMLs harbouring the translocation t(8;21) or inv(16). 
In one of the studies, upregulation of miR-126 and miR-126* was exclusive of these 
cytogenetic alterations (Li et al. 2008). In the other study, downregulation of miR-133a 
and upregulation of miR-146a characterized t(8;21) AML, whilst upregulation of miR-99a, 
miR-100 and miR-224 defined inv(16) AMLs  (Dixon-McIver et al. 2008; reviewed in Seca 
et al. 2010) (Table 2). 
Patients bearing the translocation t(15;17) were characterized by different miRNA 
expression alterations, some of them described by several independent reports. For 
example, upregulation of miR-127, miR-323, miR-368 and miR-382 was described in two 
of three different studies (Dixon-McIver et al. 2008; Li et al. 2008; Jongen-Lavrencic et 
al. 2008). Curiously, miR-134, miR-154, miR-154*, miR-299, miR-370 and miR-376a, as 
well as the above-mentioned miRNAs, are located in chromosome 14q and were all 
described as being upregulated in translocation t(15;17) AMLs (Jongen-Lavrencic et al. 
2008; Dixon-McIver et al. 2008; reviewed in Seca et al. 2010) (Table 2). 
The MLL-rearrangement AMLs have also been characterized by miRNA profiling and 
different groups have come to various conclusions. In one study, the absence of expression 
of miR-10a, miR-331 and miR-340 was reported to define this cytogenetic alteration in 
AML (Dixon-McIver et al. 2008), whilst another study found an altered expression of 24 
miRNAs in MLL rearrangements, seven of which belonging to the polycistronic miRNA 
cluster, mir-17-92 (Li et al. 2008). Another miRNA signature for MLL-rearrangement 
AMLs was identified, having 8 upregulated and 14 downregulated miRNAs (Garzon et al. 
2008b) (Table 2). Amongst the downregulated miRNAs were some tumour suppressor 
miRNAs previously known to target critical oncogenes: miR-34b [targets CDK4 and 
CCNE2 (He et al. 2007)], miR-15a [targets BCL-2 (Cimmino et al. 2005)], let-7 family 
[targets RAS (Johnson et al. 2005)], miR-29 family [targets MCL-1 (Mott et al. 2007)] and 
miR-196 [targets HOX-A7, HOX-A8, HOX-D8 and HOX-B8 (Yekta et al. 2004; reviewed 
in Seca et al. 2010)].  
The miRNA profile of 7 AML patients harbouring the translocation t(8;16)(p11;p13), 
compared with 113  other types of AML, revealed a distinctive signature of 94 miRNAs, 
most of which were found to be downregulated. A bioinformatic analysis showed that 29 
of the miRNAs found to be downregulated might be regulated by methylation. This was 
confirmed for 27 of those miRNAs, by treating the t(8;16) AML samples with 5-aza-20-
deoxycytidine (5-AZA-dC) and trichostatin A, since they were re-expressed after such 
treatment. Cross-correlation of mRNA and miRNA expression identified RET as a 
potential target of several miRNAs. In fact, miR-15a, miR-27b, miR-128, miR-195 and 
miR-218 were further confirmed, by Renilla-luciferase assay and flow cytometry after 
transfection with pre-miRs, to directly target RET (Diaz-Beya et al. 2013). 




Analysis of miRNAs expression profile of 17 AML samples with complex karyotype and 
with known TP53 status (altered - loss and/or mutation of TP53 - or unaltered) identified 
22 differentially expressed miRNAs, with miR-34a and miR-100 as the most significantly 
down- and upregulated miRNAs, respectively. Moreover, a gene expression profile 
enriched for genes belonging to p53-associated pathways (and implicated in cell cycle 
progression or apoptosis) was found in correlation with miR-34a expression. Clinically, 
low miR-34a expression and TP53 alterations were predictors of chemotherapy resistance 
and worse outcome (Rucker et al. 2013). 
miRNA signatures for specific types of AMLs bearing characteristic mutations have also 
been described. In 85 de novo AML samples (55 with NPM1 alteration and 30 with wild-
type NPM1) a distinctive pattern of miRNAs had altered expression between the two 
groups, with 36 upregulated and 21 downregulated miRNAs in NPM1 mutated samples 
(Garzon et al. 2008a) (Table 2). Amongst the upregulated miRNAs were miR-10a and 
miR-10b which were able to differentiate the two groups, as was also shown by others 
(Jongen-Lavrencic et al. 2008; Becker et al. 2010b; reviewed in Seca et al. 2010) (Table 2). 
A microarray analysis of 203 miRNAs in 21 AML samples with NPM1 mutations and 5 BM 
samples from normal stem cell healthy donors was performed, to detect differential 
expression patterns. Fourteen miRNAs were identified as having distinct expression levels 
between leukemic and non-leukemic samples; in addition, NPM1 mutant AML samples 
presented a markedly overexpression of miR-10a (Ovcharenko et al. 2011) (Table 2). In 
addition, in vitro miR-10a overexpression induced differential gene expression, with 
murine double minute 4 (MDM4) standing as a candidate target for miR-10a. MDM4 was 
further validated as a direct target of miR-10a and an inverse association between miR-
10a and MDM4 expression in NPM1 mutated AML samples was shown, implying that 
miR-10a expression may influence  biological properties in AML by interfering with the 
p53 machinery, partly regulated by MDM4 (Ovcharenko et al. 2011).  
A locked nucleic acid (LNA) based miRNA microarray platform was used to profile bone 
marrow samples of patients with cytogenetically normal AML (CN-AML) and five miRNAs 
emerged (miR-10a, let-7b and let-7c found to be overexpressed and miR-130a and miR-
335 found to be underexpressed) as capable of dichotomising AML patients according to 
their NPM1 mutational status (Bryant et al. 2012) (Table 2).  
Another study analysed miRNA and gene expression profiles of 43 cytogenetically normal 
AML patients (23 with NPM1 mutations and 20 wildtype). Out of 177 putative miRNA-
target mRNA interactions that were identified, 77 novel candidates with known or 
potential involvement in leukemogenesis were validated, such as IRF2-miR-20a, KIT-





suppressor miRNAs, such as miR-29a and miR-30c, which is observed in NPM1 mutated 
AML, may contribute to sensitivity to cytarabine (Russ et al. 2011). 
A study focusing on BAALC (Brain and Acute Leukaemia, Cytoplasmic) using miRNA 
microarrays, reported that from over 50 patients – 24 with high and 26 with low 
expression of BAALC – no differences were found in miRNA profiles. However, miRNAs 
predicted (by in silico analysis) to target BAALC mRNA were further analysed and miR-
148a presented a strong inverse correlation with BAALC expression (Langer et al. 2008). 
Additionally, AMLs harbouring CEBPA mutations revealed a characteristic miRNA 
signature, with 2 downregulated and 15 upregulated miRNAs (Marcucci et al. 2008a) 
(Table 2). Of the latter, 8 belonged to the miR-181 family, known to be involved in 
erythroid and lymphoid differentiation (Chen et al. 2004; Marcucci et al. 2008a; Choong 
et al. 2007; reviewed in Seca et al. 2010). Microarray analysis of miRNA expression in the 
AML cell line Kasumi-1 conditionally expressing CEBPA showed that 18 miRNAs 
presented altered expression, when compared to the parental cell line. Among those was 
miR-29b, which was shown to be downregulated in AML patients with impaired CEBPA 
function or loss of chromosome 7q. As CEBPA selectively regulates miR-29b, this study 
provided a rationale for miR-29b suppression in AML patients with loss of chromosome 
7q or CEBPA deficiency (Eyholzer et al. 2010b). 
Another study profiled a miRNA signature for meningioma 1 (MN1) high-expression 
AMLs. This study identified five upregulated miRNAs (miR-126, miR-126*, miR-129-5p, 
miR-130b and miR-424) and five downregulated miRNAs (miR-16, miR-19a, miR-20a, 
miR-100 and miR-196a) (Langer et al. 2009) (Table 2). 
Additionally, when analysing AMLs bearing FLT3-ITD, three miRNAs – miR10a, miR-10b 
and miR-155 – were found to be upregulated in FLT3-ITD when compared with FLT3-wt 
patients (Garzon et al. 2008b) (Table 2). A study including 64 CN AMLs with adverse 
molecular characteristics – FLT3-ITD, wildtype NPM1 or both, found 8 miRNAs 
associated with event-free survival (Marcucci et al. 2008b), none of them overlapping with 
previously published results (Garzon et al. 2008b; reviewed in Seca et al. 2010). Another 
study showed that overexpression of miR-124, miR-128-1, miR-194, miR-219-5p, miR-
220a and miR-320 was positively associated with the risk of an event (failure to achieve 
complete remission, relapse or death) whilst miR-181a and miR-181b overexpression was 
negatively associated with that risk. These authors also investigated gene-expression 
signatures to identify genes that could be regulated by the depicted miRNAs. Some 
predicted targets of the miR-181 family had an inverse correlation with these miRNAs’ 
expression (TLR4, CARD8, CASP1 and IL1B), suggesting that miR-181 family 
downregulation can be linked to more aggressive AMLs (Marcucci et al. 2008b). Another 
study was able to directly correlate miR-181a expression with a better prognosis in CN 




AML, independently of other variables including CEBPA mutations (Schwind et al. 2010; 
reviewed in Seca et al. 2010). More recently, it was shown that increased expression of 
miR-181a and miR-181b is also significantly associated with favourable overall survival in 
cytogenetically abnormal AML (CA-AML) patients (Li et al. 2012). Moreover, when 
analysing 183 CA-AML patients, upregulation of a gene signature composed of 4 potential 
miR-181 targets (including HOXA7, HOXA9, HOXA11, and PBX3) associated with 
downregulation of miR-181 family members, was shown to be an independent predictor of 
adverse overall survival. Furthermore, in vitro and in vivo studies have shown that ectopic 
expression of miR-181b promoted apoptosis and inhibited viability and proliferation of 
leukemic cells, delaying leukemogenesis; in addition, these effects could be reversed by 
forced expression of PBX3. These results showed that upregulation of the above 
mentioned homeobox genes resulted from the downregulation of miR-181 family members 
and probably contribute to the poor prognosis of patients with nonfavorable CA-AML (Li 
et al. 2012). 
Overexpression of miR-191 and miR-199 was correlated with shorter overall survival and 
shorter event-free survival in a group of intermediate and poor prognosis karyotypes 
(Marcucci et al. 2008b). Cytogenetic prognostic risk could also be determined by the 
expression of two other miRNAs: miR-9 and let-7b, whose expression was found to be low 
in good prognosis groups and high in intermediate or adverse AMLs (Dixon-McIver et al. 
2008; reviewed in Seca et al. 2010). 
Mutations in the Wilms tumor 1 gene (WT1) occur in approximately 10% of adults with 
CN-AML, and conflicting results have been reported that they confer a worse outcome 
(Virappane et al. 2008; Summers et al. 2007) or have no prognostic impact (Gaidzik et al. 
2009; Damm et al. 2010). The synonymous single nucleotide polymorphism (SNP) 
rs16754 of this gene has also been reported to be associated with outcome but results have 
not been concordant between studies. An association between the homozygous A allele 
and significantly shorter relapse-free survival and overall survival has been found in some 
studies (Damm et al. 2010) while other studies have found no association with such 
outcomes (Hollink et al. 2010; Ho et al. 2011). Therefore, gene and miRNA expression 
profiles of 433 AML patients were analysed for associations with rs16754 polymorphism; 
however, no distinct expression patterns were found to be associated with any rs16754 
















downregulated miRNAs References 
t(8;21) miR-126, miR-126*  (Li et al. 2008) 
 miR-146a miR-133a (Dixon-McIver et al. 2008) 
inv(16) miR-126, miR-126*  (Li et al. 2008) 
 miR-99a, miR-100, miR-
224 
 (Dixon-McIver et al. 2008) 
t(15;17) miR-127, miR-134, miR-
323, miR-376a, miR-382  
 (Jongen-Lavrencic et al. 2008) 
 miR-127, miR-154, miR-
154*, miR-299, miR-323, 
miR-368, miR-370 
 (Dixon-McIver et al. 2008) 
 miR-368, miR-382  (Li et al. 2008) 
MLL 
rearrangements 
 miR-10a, miR-331, miR-340 (Dixon-McIver et al. 2008) 
 miR-17-3p, miR-17-5p, 
miR-18a, miR-19a, miR-
19b, miR-20a, miR-92 
 (Li et al. 2008) 
  let-7, miR-15a, miR-29a, 
miR-29b, miR-29c, miR-
34b, miR-196a 
(Garzon et al. 2008b) 
NPM1 mutation miR-10a, miR-10b  (Jongen-Lavrencic et al. 2008) 
 miR-10a, miR-10b  (Garzon et al. 2008a) 
 miR-10a, miR-10b  (Becker et al. 2010b) 
 miR-10a  (Ovcharenko et al. 2011) 






 (Marcucci et al. 2008a) 
high MN1 miR-126, miR-126*, miR-
129-5p, miR-130b, miR-
424 
miR-16, miR-19a, miR-20a, 
miR-100, miR-196a 
(Langer et al. 2009) 
FLT3-ITD miR-10a, miR-10b, miR-
155 
 (Garzon et al. 2008b) 
Adapted from (Seca et al. 2010) 
 
Recently, a study focusing on leukemias of ambiguous lineage (which represent a 
heterogeneous category of acute leukemias which cannot be classified as either AML or 
ALL) analysed their miRNA expression profiles. The study analysed sixteen cases of acute 
leukemia of ambiguous lineage and 17 cases of clinically defined acute leukemias: AML (n 




= 7), B-ALL (n = 6) and T-ALL (n = 4) were analysed. Leukemias of ambiguous lineage did 
not segregate as a separate entity but exhibited miRNA expression profiles similar to AML, 
B-ALL or T-ALL. Using only 5 of the most lineage discriminative miRNAs (Wang et al. 
2010b; Mi et al. 2007) was enough to define acute leukemia of ambiguous lineage as either 
AML or ALL (de Leeuw et al. 2013). 
MiRNA microarray analysis of 15 chemoresistant and 18 chemosensitive AML bone 
marrows identified 3 significantly upregulated miRNAs: miR-363, miR-532-5p and miR-
342-3p in chemoresistant samples (Mosakhani et al. 2013b). 
In order to identify miRNAs that are significant prognostic determinants, independent 
from other known prognostic factors, a miRNA analysis was performed in a discovery 
cohort (n = 167) and a validation cohort (n = 409) of a heterogeneous AML population. 
miR-212 was shown to be an independent prognostic factor, significantly associated with 
prolonged overall survival and event-free and relapse-free survival in the discovery cohort. 
These results were subsequently confirmed in the independent validation cohort, with the 
prognostic significance of high expression of miR-212 not correlating with any 
(cyto)genetic subtypes of AML (Sun et al. 2013). 
 
3.2 THE ROLE OF MIRNAS IN AML 
 MIRNAS IN HEMATOPOIETIC DIFFERENTIATION 
As mentioned above, AML is a malignance associated with lack of differentiation of 
hematopoietic cells. This cellular process is therefore a candidate pathway for deregulated 
miRNAs to interfere with, leading to AML progression. Indeed, some miRNAs have been 
shown to play a role in hematopoietic differentiation and have been linked with AML 
progression in specific genetic backgrounds. AML1/ETO is a fusion protein characteristic 
of translocation t(8;21) in AMLs. AML1 normal expression was shown to downregulate 
miR-24 transcription but patients bearing the translocation t(8;21) overexpressed miR-24, 
which inhibited a mitogen-activated protein kinase (MAPK) phosphatase (MKP-7), thus 
leading to the activation of downstream partners (Zaidi et al. 2009). miR-24 was also 
shown to block myeloid differentiation and to accelerate cellular proliferation (Zaidi et al. 
2009; reviewed in Seca et al. 2010).  
The miR-193a has been shown to be downregulated in t(8;21) AMLs. AML1/ETO has been 
shown to act as a transcriptional repressor of AML1 target genes triggering the 
heterochromatic silencing of miR-193a. Suppression of miR-193a is associated with 
increased oncogenic activity of the fusion protein AML1-ETO, because miR-193a directly 





CCND1 and MDM2. Demethylation, RNAi inhibition of AML1/ETO or ectopic expression 
of miR-193a induced G1 arrest, apoptosis and restored leukemic cell differentiation. A 
feedback circuitry involving miR-193a and AML1/ETO/DNMTs/HDACs seems to be 
involved in AML differentiation. Moreover, in vivo experiments showed that ectopic 
expression of miR-193a reduced tumor size (Li et al. 2013a).  
Another miRNA that has been correlated with AML t(8;21) carriers is miR-223 (Fazi et al. 
2007). Patients’ primary leukemia blasts showed a low level of miR-223, a previously 
known regulator of myelopoiesis (Fazi et al. 2005). This miRNA expression is decreased 
by the interaction of the AML1/ETO fusion protein with the miRNA promoter region. 
AML1/ETO has the capacity to oligomerise with histone deacetylase (HDAC) and DNA 
methyltransferases (DNMTs) bringing them to the AML1-binding site on the pre-miR-223 
gene, hence silencing miR-223. Demethylating treatment, RNAi against AML1/ETO or 
ectopic expression of miR-223 restored cell differentiation, showing the importance of this 
miRNA in the normal myelopoiesis. Interestingly, another study focusing on miR-223 and 
AML showed no association between the expression of this miRNA and hypermethylation 
of its promoter region; furthermore, this study showed that miR-223 suppression in AML 
was rather due to impaired miR-223 upstream factors mediated by the conserved 
CEBP/PU.1 responsive element in front of the pri-miR-223 transcript start site (Eyholzer 
et al. 2010a). The known role of miR-223 in myelopoiesis has been supported by a recent 
study that correlates CEBPA and E2F1 transcription factors levels with miR-223 
expression. CEBPA was shown to upregulate miR-223 expression, which in turn directly 
targets E2F1 3’-UTR, inhibiting its translation. Further studies elucidated that E2F1 is also 
a repressor of miR-223 by binding to its promoter region, producing a negative feedback 
loop. It was also shown that overexpression of miR-223 blocked cell proliferation allowing 
cells to differentiate, thus confirming its role in myelopoiesis (Pulikkan et al. 2010; 
reviewed in Seca et al. 2010).  
miR-125 has been associated with the t(2;11) cytogenetic translocation (Bousquet et al. 
2008). Indeed, AML patients with t(2;11)(p21;q23) translocation showed a big increase in 
miR-125b expression; additionally, in vitro experiments showed that miR-125b was able 
to both hamper primary human CD34+ cell differentiation and inhibit myelo-monocytic 
differentiation in HL-60 and NB4 leukemic cell lines. Accordingly, upregulation of miR-
125b may represent a new mechanism of myeloid cell transformation in patients carrying 
the t(2;11) translocation (Bousquet et al. 2008; reviewed in Seca et al. 2010). In another 
study, a bone marrow transplantation model was used to analyse the role of miR-125b in 
leukemogenesis. Transduction of miR-125b resulted in expansion of hematopoietic cells 
although no leukemic transformation was observed as in other studies (Bousquet et al. 




2010). miR-125b was shown to accelerate myeloid tumours induced by a C-terminal 
mutant of CEBPA (Enomoto et al. 2012). 
Another miRNA shown to be specifically overexpressed in AML patients with MLL 
rearrangement is miR-196b (Popovic et al. 2009). The overexpression of miR-196b in 
bone marrow progenitor cells seems to increase proliferation and survival capacity, as well 
as to partially block differentiation, indicating that miR-196b plays a role in the 
development of MLL leukemias (Popovic et al. 2009; reviewed in Seca et al. 2010). More 
recently, miR-196b has been shown to directly target the ERG transcription factor. In 
addition, during in vitro differentiation of CD34+ cells the miR-196b expression decreased 
with time, indicating a role for miR-196b in early hematopoiesis (Coskun et al. 2011). 
HIF-1α has been shown to induce differentiation of AML cells (Liu et al. 2006; Song et al. 
2008). miR-17 and miR-20a were shown to be repressed by HIF-1α, through its 
downregulation of c-Myc expression. Ectopic expression of miR-17 or miR-20a partially 
rescued the growth inhibition and G1 arrest and attenuated HIF-1a-triggered 
differentiation, indicating that there is a tight loop regulation between these factors. This 
rescue was achieved through miR-17 and miR-20a direct interaction with p21 and STAT3, 
reducing their expression. Both p21 and STAT3 have been shown to be involved in the 
Jak-STAT signalling pathways, reported as closely related to cell differentiation (Weber-
Nordt et al. 1998). Moreover, in vivo experiments showed that miR-20a contributes to 
HIF-1α-induced differentiation of leukemic cells (He et al. 2013).  
The analysis of 48 BMs from AML patients, compared with BM samples from healthy 
donors, revealed a higher expression of miR-100 in AML samples. miR-100 
overexpression was associated with an arrest of human granulocyte and monocyte 
differentiation and increased cell survival. It was shown to directly target RBSP3, a 
phosphatase shown to be is involved in myeloid cell differentiation and cell proliferation 
(Kashuba et al. 2009), via the dephosphorylation of RB and the release of E2F1, thus 
inducing progression through the G1/S transition and promoting S-phase entry (Zheng et 
al. 2012).  
The let-7c was shown to be downregulated in PML/RARα-positive AML blasts when 
compared to normal promyelocytes (Careccia et al. 2009). Ectopic expression of let-7c 
promoted granulocytic differentiation of AML cell lines and primary blasts. PBX2, a 
protein whose aberrant expression enhances HoxA9-dependent leukemogenesis, was 
identified as a novel let-7c direct target, showing its involvement in the AML phenotype 
(Pelosi et al. 2013). 
Two other miRNAs shown to be downregulated in AML patients were miR-29a and miR-
142-3p (Wang et al. 2012a). Their expression was increased during ATRA and PMA 





stem/progenitor cells. Both miRNAs directly inhibited cyclin T2, preventing the release of 
hypophosphorylated retinoblastoma and resulting in the induction of monocytic 
differentiation. In addition, miR-29a was shown to directly target cyclin-dependent kinase 
6, and miR-142-3p to target TGF-β–activated kinase 1/MAP3K7 binding protein 2, which 
are involved in the regulation of both monocytic and granulocytic differentiation. Using 
lentivirus-mediated gene transfer, enforced expression of either miR-29a or miR-142-3p 
in BM CD34+ cells derived from 3 AML patients led to a decrease in their target protein 
levels and partially overcame the differentiation arrest in AML blasts (Wang et al. 2012b). 
Interestingly and opposingly, in another study miR-29a was shown to be highly expressed 
in both human and mouse hematopoietic stem cells (HSC). In this study, miR-29a 
chimeric mice showed an abnormal acquisition of self-renewal capability by myeloid 
progenitors and development of a myeloproliferative disorder that progressed to AML. It 
also promoted progenitor proliferation by accelerating G1 to S/G2 cell cycle transitions 
thus suggesting that miR-29a participated in the initiation of AML by converting myeloid 
progenitors into self-renewing, stem-like cells (Han et al. 2010).  
AML cell lines exposed to vitamin D3 acquire features of normal monocytes and are 
arrested in the G1 phase of the cell cycle, due to the upregulation of p27Kip1 and p21Cip1. 
miR-181a was shown to directly target p27Kip1, attenuating the effect of vitamin D3 on the 
expression of monocytic differentiation markers and reducing the G1 block, suggesting 
that expression of miR-181a may contribute to the malignant phenotype of AML cells 
(Mishra et al. 2009). Vitamin D3-mediated monocytic differentiation of AML cells 
induced miR-26a expression, while its expression was shown to be downregulated in AML 
blasts (Salvatori et al. 2011). E2F7 was identified as a novel direct target of miR-26a and it 
was shown that E2F7 promotes cell cycle progression and inhibits monocytic 
differentiation of AML cells through binding to the cyclin-dependent kinase inhibitor 
p21CIP1/WAF1 promoter, repressing its expression. Thus, miR-26a regulation of E2F7 
expression has a role in monocytic differentiation and leukemogenesis (Salvatori et al. 
2012). 
Analysis of miR-370 expression in BM samples from 48 de novo AML patients showed a 
significantly reduction of this miRNA expression, when compared to healthy controls, 
while miR-370 expression in patients in complete remission showed an increase in this 
miRNA expression, close to the expression seen in the controls. miR-370 expression was 
shown to be upregulated after treatment with 5-aza-20-deoxycytidine, a DNA 
demethylating agent, providing a possible mechanism for its downregulation. 
Additionally, FoxM1, a well-established oncogenic factor promoting cell cycle progression 
(Nakamura et al. 2010), was shown to be a direct target of miR-370. Its ectopic expression, 
in HL60 and K562 cells, led to cell growth arrest and senescence (Zhang et al. 2012). 




High BAALC expression level is associated with poor outcome in CN-AML patients. miR-
3151 was discovered in intron 1 of BAALC (Stark et al. 2010; Schotte et al. 2011) and its 
expression was associated with shorter disease-free and overall survival. Patients 
exhibiting high expression of both miR-3151 and BAALC had worse outcome than patients 
expressing low levels of either gene or both genes, with both markers contributing 
independently to poor outcome in CN-AML patients (Eisfeld et al. 2012). 
In a study performed in HL-60 cells, it was shown that transferrin receptor 1 (TfR-1), 
involved in increased proliferation and decreased differentiation of leukaemic cells 
(Chitambar et al. 1983), is a target of miR-320 (Schaar et al. 2009). This miRNA emerges 
as a potential therapeutic target for TfR-1 overexpressing malignancies such as breast 
carcinoma, colorectal cancer or AML (Schaar et al. 2009; Brookes et al. 2006; Kwok and 
Richardson 2002; Yang et al. 2001). 
Functional loss of CEBPA, a key transcription factor involved in the regulation of cell 
proliferation and differentiation in the hematopoietic system, can result in a 
differentiation block in granulopoiesis and contribute to leukaemic transformation 
(Hackanson et al. 2008). DNA methylation of CEBPA upstream promoter region has been 
correlated with t(15;17) and inv(16) AMLs. The use of demethylating agents, in vitro, led to 
an increase of CEBPA mRNA but, surprisingly, to a decrease of CEBPA protein expression. 
In addition, it was shown that miR-124a targets CEBPA mRNA, both by luciferase reporter 
assay (using a vector containing the 3’-UTR of CEBPA mRNA) and by analysis of CEBPA 
protein levels following transfection of K562 cells with miR-124a. Indeed this miRNA, 
often silenced by epigenetic mechanisms in AML, becomes activated after demethylation 
treatment and targets the 3’-UTR of CEBPA mRNA (Hackanson et al. 2008). This might 
explain why some patients respond well to epigenetic therapy whilst others do not 
(Hackanson et al. 2008; reviewed in Seca et al. 2010). 
 
 MIRNAS AND EPIGENETIC REGULATION     
DNA methylation is a recognised regulatory molecular mechanism that leads to gene 
transcriptional silencing (Kim et al. 2009) and plays a role in AML development (Plass et 
al. 2008). The role of miRNAs in the epigenetic field is being unveiled (Kasinski and Slack 
2011) and miR-29b has been shown to regulate DNA methyltransferases (DNMTs) in the 
context of leukaemia (Garzon et al. 2009b). This miRNA targets DNMT3A and DNMT3B 
directly and DNMT1 indirectly by interfering with Sp1, a DNMT1 transcription factor. 
Overexpression of miR-29b, in leukaemic cell lines, led to global DNA hypomethylation 
and re-expression of the tumour suppressor genes ESR1 and cyclin-dependent kinase 





 MIRNAS AND APOPTOSIS  
It has also been shown that miR-29b expression reduced cell growth and induced 
apoptosis in cell lines and primary AML samples. Furthermore reduced tumour growth 
was found in a human leukaemia xenograft model in mice, following injection of miR-29b 
into the tumours (Garzon et al. 2009a). Moreover, Mcl-1 was shown to be a miR-29b 
target and the analysis of 45 primary AML samples revealed an inverse correlation 
between miR-29b and Mcl-1 expression (Garzon et al. 2009a; reviewed in Seca et al. 
2010)).  
Cyclic AMP-responsive element binding protein (CREB) is occasionally overexpressed in 
AML (Pigazzi et al. 2007; Shankar et al. 2005). Myeloid cell lines, known to overexpress 
CREB, presented significantly lower levels of miR-34b. Furthermore, the exogenous 
expression of miR-34b directly targeted CREB mRNA, diminishing CREB protein levels 
and altering CREB target gene expression including several proteins known to regulate 
apoptosis: BCL-2, cyclin A1, cyclin B1, cyclin D, NF-KB, JAK1 and STAT3 (Pigazzi et al. 
2009; reviewed in Seca et al. 2010). Downregulation of miR-34b in cell lines and AML 
patients was shown to be, in part, due to promoter methylation (Pigazzi et al. 2013). 
Moreover, an inverse correlation between miR-34b and CREB expression was observed in 
78 pediatric AML patients, supporting the in vitro experimental results (Pigazzi et al. 
2009). 
miR-181a was shown to be downregulated in a HL-60 drug resistant cell line, when 
compared with its parental sensitive one. Bcl-2 was shown to be a target of miR-181a, 
which overexpression activated the apoptosis pathway by cytochrome C release and 
caspase-9/caspase-3 activation leading to sensitization of cells to cytarabine treatment 
(Bai et al. 2012). Another member of the miR-181 family, miR-181b, was shown to be 
overexpressed in AML patients. It directly targets MLK2, a member of the MAPK pathway 
important for p53-dependent apoptosis (Brown and Benchimol 2006), inducing cell 
survival through blockage of apoptosis (Chen et al. 2010). 
Mutations and/or overexpression of c-Kit proto-oncogene frequently occur in subsets of 
AML. c-Kit is targeted by miR-193a/b, inhibiting its translation and targeting it for 
degradation. Their expression is inversely correlated in bone marrow samples and 
restoration of miR-193a/b expression in AML cells resulted in increased apoptosis and 
inhibited cell growth (Gao et al. 2011a; Gao et al. 2011b). 
Inhibiting miR-32 expression was shown to increase apoptosis and sensitize AML cells to 
cytarabine. As miR-32 directly targets Bim, a known proapoptotic factor, its 
downregulation allows Bim increased expression and activity (Gocek et al. 2011). 




In HL-60 cells, the inhibition of miR-21 using antisense oligonucleotides, contributed to 
the sensitization of the leukemic cells to cytarabine through an increase in apoptosis (Li et 
al. 2010b). 
 
3.2.4 MIRNAS AND MULTIDRUG RESISTANCE  
In a study using the HL-60 AML cell line, Zhao and colleagues reported that miR-138 
could be related with multidrug resistance of leukaemic cells. This miRNA was found in 
lower amounts in a HL-60 resistant cell line when compared with its parental cell line. 
Additionally, transfection of miR-138 into the HL-60 resistant cells was able to reverse P-
glycoprotein-mediated resistance (by regulation of MDR1 transcription) and to induce 
apoptosis via regulation of the expression of Bcl-2 and Bax proteins (Zhao et al. 2010; 
reviewed in Seca et al. 2010). 
 
3.3 CAUTION NEEDED IN THE ANALYSIS OF FUNCTIONAL STUDIES  
Publications on miRNA expression profiles have not always been providing concordant 
results. This observation could be explained by the different AML samples used, with 
different cytogenetic and molecular characteristics, and the different platforms used to 
generate miRNA expression profiles. Normalisation of miRNA expression to other small 
RNAs (snRNA or tRNAs) other than miRNAs themselves may provide more reliable 
results. One of the above-mentioned studies has made a normalisation of the results for 
miR-223 expression which was shown to be uniformly expressed across the set of samples 
(Debernardi et al. 2007). However, miR-223 was shown to be differently expressed 
amongst AML samples in other studies (Fazi et al. 2007; Pulikkan et al. 2010). The 
method of RNA extraction and analysis of RNA quality could also interfere with the 
specific miRNA quantities detected (Becker et al. 2010a; Ach et al. 2008).  
Despite these drawbacks, miRNA profiling can add extra knowledge towards better 
treatment of AML. Along with copy number alteration studies (Kim et al. 2012; Walter et 
al. 2009), miRNA expression profiles and functional studies of individual miRNAs 
aberrantly expressed in AMLs can introduce new insights into the perception of 
leukemogenesis, possibly improving diagnosis and identifying better prognostic markers 
as well as contributing to more tailored patient treatment.  
Additionally, miRNAs have been proposed to be promising serum biomarkers for the 
detection of cancer (Mitchell et al. 2008; Van Roosbroeck et al. 2013; Redova et al. 2013). 
In fact, various recent studies have revealed that some miRNAs may serve as potential 





leukemia patients. In addition, the ratio of miR-92a/miR-638 (a miRNA shown to be 
equally expressed in all the samples, regardless of age, sex or leukemia classification) in 
plasma was valuable to distinguish healthy donors from acute leukemia patients (Tanaka 
et al. 2009). The expression of miR-150 and miR-342 in plasma was also shown to be 
associated with AML (Fayyad-Kazan et al. 2013). Another study found 6 miRNAs (miR-
10a-5p, miR-93-5p, miR-129-5p, miR-155-5p, miR-181b-5p and miR-320d) that had 
significantly different expression levels in AML serum samples compared with control 


























































4. MIRNAS AND CML 
CML is associated with the upregulation of miR-17-92 which is directly activated by c-
MYC (O'Donnell et al. 2005). miR-17-92 cluster has also been shown to be induced by 
members of the E2F family of transcription factors (Woods et al. 2007). In addition, it is 
known that miR-17-5p and miR-20a, two miRNAs members of the miR-17-92 cluster, 
directly target and downregulate the expression of E2F1 in a negative feedback loop of 
transcriptional regulation (O'Donnell et al. 2005). This feedback loop counteracts the 
proliferative and apoptotic roles of E2F transcription factors allowing the fine tuning of 
this mechanism (Sylvestre et al. 2007; Woods et al. 2007; O'Donnell et al. 2005). 
Additionally, miR-17-92 cluster was found to be overexpressed in CML CD34+ cells from 
patients in chronic phase but not in blast crisis, when compared with normal CD34+ cells 
(Venturini et al. 2007). K562 CML cells treated with imatinib or with siRNAs for BCR-ABL 
or c-MYC presented downregulation of miR-17-92, showing that the BCR-ABL-MYC 
pathway controls the expression of these miRNAs (Venturini et al. 2007). 
Imatinib resistant K562 cells, which overexpress c-MYC, were shown to have 
downregulation of miR-144/451. Restoration of miR-144/451 sensitized imatinib resistant 
cells to apoptosis, providing evidence for the role of Myc-miR144/451 pathway in CML 
drug resistance (Liu et al. 2012). Some studies have shown that there is a reciprocal 
regulatory loop between BCR-ABL and miR-451 (Lopotova et al. 2011; Scholl et al. 2012). 
Additionally, miR-196b, a miRNA whose expression was found decreased in CML patients, 
was also shown to directly target BCR-ABL decreasing cell proliferation and retarding the 
cell cycle (Liu et al. 2013b). 
CGH (comparative genomic hybridization) analysis identified a tumor suppressor miRNA, 
miR-203, whose expression is decreased in hematopoietic malignancies, by both genetic 
(due to its location in a fragile chromosomal region) and epigenetic (due to 
hypermethylation) mechanisms. miR-203 controls the expression of ABL, and also the 
expression of BCR-ABL fusion protein. In addition, its reintroduction into the CML cell 
lines K562 and KCL-22 resulted in decreased expression of ABL and BCR-ABL fusion 
protein levels, inhibiting tumor cell proliferation in an ABL-dependent manner (Bueno et 
al. 2008a). In a recent study, overexpression of miR-203 in cells bearing BCR-ABL T315I 
mutation (known to confer resistance to tyrosine kinase inhibitors) inhibited cell growth 
and colony formation ability and increased sensitivity to imatinib, therefore antagonizing 
the main mechanism of resistance (Li et al. 2013c). 
miR-30a was also shown to directly target BCR-ABL and is often found underexpressed in 
bone marrow from CML patients. In K562 CML cells, overexpression of miR-30a reduced 




ABL and BCR-ABL protein expression, decreasing proliferation and arresting cell cycle 
progression between G1 and S (Liu et al. 2013a). In addition, overexpression of miR-30a 
was shown to decrease Beclin-1 and ATG5 expression (and subsequently autophagy), 
enhancing imatinib-induced apoptosis (Yu et al. 2012). 
miR-138 has also been shown to repress BCR-ABL expression by targeting the coding 
region of the ABL gene as well as targeting the 3’-UTR of CCND3. In K562 and Ku812 
CML cell lines, the tumor suppressor activity of miR-138 was demonstrated by the 
induction of cell cycle arrest at G0/G1, inhibition of cell proliferation and colony formation 
and the enhancement of imatinib-induced apoptosis. The upregulation of miR-138 
expression upon imatinib treatment is associated with the enhancement of GATA1 activity, 
which binds to the miR-138 promoter (Xu et al. 2012). 
Loss of miR-328 occurs in blast crisis of CML in a BCR-ABL dependent manner. Its re-
expression restored differentiation and hampered survival of leukemic blasts by targeting 
the mRNA encoding the survival factor PIM1 and through inhibition of the translational 
regulator poly(rC)-binding protein hnRNP E2, inhibiting its interaction with 
hematopoietic transcription factor CEBPA (Eiring et al. 2010). 
In K562 CML cells, miR-181a was shown to directly target RalA, a downstream molecule 
of BCR-ABL fusion protein in the Ras signaling pathway. miR-181a overexpression led to a 
decrease in cell growth and induced G2-phase arrest and apoptosis partially through 
targeting RalA (Fei et al. 2012). Other members of the miR-181 family have been shown to 
be deregulated in CML. In a model of Lyn-mediated imatinib-resistant CML, miR-181b 
and miR-181d were shown to be downregulated and miR-181b was shown to directly target 
Mcl-1 3´-UTR (Zimmerman et al. 2010). A recent study designed to find miRNAs involved 
in imatinib response, in 9 CML patients including 4 imatinib-resistant and 5 imatinib-
responder patients, found miR-181c as the only differentially expressed miRNA 
(Mosakhani et al. 2013a). 
In K562 CML cells CCN3, a negative growth regulator, was shown to be regulated by miR-
130a/b, which are BCR-ABL dependent miRNAs. Downregulation of CCN3 expression 
confers growth advantage and survival means for CML cells (Suresh et al. 2011). By 
analysis of miRNAs expression in CML cell lines and patients comparing to non-CML cell 
lines and healthy donors, miR-31, miR-155 and miR-564 were found downregulated in 
CML with this downregulation being dependent on BCR-ABL activity. The decreased 
expression of these miRNAs led to the upregulation of several putative targets, namely 
CBL, E2F3, cyclin D1, K-ras and Akt2 which are involved in distinct signaling pathways 
such as MAPK, ErbB, mTOR and VEGF related with cell survival and uncontrolled cell 
proliferation (Rokah et al. 2012). In CML patients the expression of miR-223 is inversely 





expression of this miRNA. PTBP2 and MEF2C, were validated as miR-223 targets, and 
their expression is associated with cell survival and proliferation which can eventually help 
in disease progression (Agatheeswaran et al. 2013). 
Although the BCR-ABL oncoprotein is a pivotal factor in CML pathogenesis there are 
some miRNAs that present abnormal expression, independently of BCR-ABL activity. 
Analysis of miRNA expression in blood samples from newly diagnosed CML patients 
before and within the first two weeks of imatinib therapy identified an increase in the 
expression of miR-150 and miR-146a, and a reduction in the expression of miR-142-3p 
and miR-199b-5p. The aberrant expression levels of these miRNAs tended to normal levels 
after the two weeks of imatinib therapy (Flamant et al. 2010). Another study, comparing 
miRNA expression profiles of K562 imatinib sensitive and imatinib resistant cells, 
identified miR-212 as being downregulated in resistant cells; the authors correlated miR-
212 expression with the efflux pump ABCG2 and further confirmed the direct targeting of 
ABCG2 by miR-212 (Turrini et al. 2012). 
Microarray analysis identified differential expression profiles of 49 miRNAs in CML 
patients at diagnosis, in hematological relapse, therapy failure, blast crisis and major 
molecular response. Among those miRNAs, miR-150 was shown to be downregulated in 
patients at diagnosis, in the majority of patients with hematological relapse and in blast 
crisis (Machova Polakova et al. 2011). It was also shown that miR-150 inversely correlates 
with the expression of MYB (Machova Polakova et al. 2011), which has been shown to be a 
target of miR-150, and shown to be required for BCR-ABL dependent leukemogenesis 
(Lidonnici et al. 2008). Another analysis of miRNA expression comparing mononuclear 
and CD34+ cells from patients with CML with healthy controls revealed that miR-10a, 
miR-150 and miR-151 were downregulated, while miR-96 was upregulated in CML cells. 
miR-10a expression was shown to be inversely correlated with upstream stimulatory 
factor 2 (USF2). The USF2 overexpression increased cell growth, while downregulation of 
miR-10a was shown not to be dependent on BCR-ABL activity and contributed to the 
increased cell growth of CML cells (Agirre et al. 2008). 
In K562 CML cells, miR-29 was shown to target and downregulate the expression of 
RNase-L, inhibiting proliferation in vitro and tumor growth in a xenograft model (Lee et 
al. 2013). miR-29b was shown to target and decrease the expression of ABL and the 
enforced expression of his miRNA, in K562 cells, inhibited cell growth and colony 
formation ability and inducing apoptosis (Li et al. 2013b). 
Other studies with K562 cells showed that miR-21 directly targets PDCD4 and that 
downregulation of miR-21 using antimiR-21 suppressed cell migration, promoted cell 
apoptosis, and inhibited cell growth (Hu et al. 2010a) with a synergistic effect with arsenic 
trioxide having been found (Li et al. 2010a; Gu et al. 2011). 




miR-326 was recently shown to target Smo, a member of the Hedgehog signaling pathway, 
resulting in decreased cell proliferation and elevated rate of apoptosis in CML CD34+ cells. 
As Hedgehog signaling has been proven as a functional pathway for leukemic stem cell, 
loss of this pathway impairs the development of BCR-ABL-induced CML and depletes 
CML stem cells (Babashah et al. 2013). 
In spite of imatinib’s outstanding success in treating CML patients, there are around 20-
25% patients that have primary resistance to imatinib and show signs of persistent 
disease. A miRNA expression signature associated with imatinib resistance was identified 
by analysis of BM mononuclear cells from patients, with Ph+ CML, that had complete 
cytogenetic response at 12 months compared with primary resistant patients. A group of 
19 miRNAs that may predict clinical resistance to imatinib was identified, with 18 of them 
being downregulated (miR-7, miR-23a, miR-26a, miR-29a, miR-29c, miR-30b, miR-30c, 
miR-100, miR-126#, miR-134, miR-141, miR-183, miR-196b, miR-199a, miR-224, miR-
326, miR-422b and miR-520a) and only one upregulated (miR-191). Among these 
miRNAs, miR-29c, miR-183 and miR-199a have been predicted to target drug 
transporters, ABCB6, ABCA1 and ABCC5 respectively. As second generation tyrosine 
kinase inhibitors are effective in patients with imatinib resistance, the identification of 
predictors of resistance to imatinib is important to distinguish the patients that should not 
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miRNAs are important regulators of distinct biological processes and are tightly related 
with several diseases, including cancer. In the last years, miRNAs have been shown to play 
an important role in drug resistance/sensitivity to anticancer drugs. This chapter first 
addresses the phenomenon of drug resistance in cancer cells. It then describes the role of 
miRNAs in drug resistance or drug sensitivity, including a review of the role of miRNAs 
and their validated targets in cancer drug resistance. Furthermore, it focuses on miRNAs 
that target cellular proteins related to drug resistance such as p53 or proteins involved in 
cellular processes such as apoptosis, autophagy, DNA damage response, epithelial to 
mesenchymal transition and cancer stem cell phenotype, drug efflux or drug metabolism. 
In addition, the non-genetic acquisition of drug resistance through the transfer of miRNAs 
from drug resistant to drug sensitive cells via microvesicles or exosomes is also discussed. 
Finally, the known miRNA polymorphisms associated with drug resistance are addressed. 




1. Cancer drug resistance 
Chemotherapy is an important treatment modality for many types of cancer and it is the 
main treatment for advanced and surgically resectable cancers. Targeted therapies have 
been more recently developed with the emergence of small molecules which target specific 
kinases or receptors in the cell that are known to be deregulated in cancer. Despite the 
benefits in improving overall survival and quality of life for patients, the therapeutic 
success of both conventional chemotherapy and targeted therapeutics is often limited due 
to drug resistance [reviewed in (Fojo, 2007; Broxterman et al., 2009; Stegmeier et al., 
2010)]. 
Cancer drug resistance may be intrinsic, based on genetic characteristics of tumor cells 
that are insensitive to therapeutic agents even before treatment - intrinsic resistance - or 
may appear de novo, after treatment with a chemotherapeutic agent - acquired resistance. 
This resistance enables the tumor cells to escape to the cytotoxic/cytostatic effect of 
anticancer drugs and thus allows the tumor to persist and eventually progress. 
Cancer drug resistance has been thoroughly studied in cell lines, animal models and 
cancer patients, in order to elucidate the cellular and molecular mechanisms involved. 
These mechanisms may comprise genetic alterations, such as a particular gene 
amplification, translocations and mutations, or epigenetic modifications that alter the 
function of pivotal genes [reviewed in (Fojo, 2007; Wilting and Dannenberg, 2012)]. In 
any of the cases, the mechanisms are generally divided into two main groups: those that 
disturb the delivery and maintenance of the drugs in the cells and those arising from 
molecular alterations that affect drug sensitivity [reviewed in (Gottesman et al., 2002)].  
Cancer drug resistance has been shown to be very hard to tackle, mostly due to two 
factors: i) the intra-tumour heterogeneity [(due to expansion of multiple clones, some 
being more aggressive than others (Gerlinger et al., 2012)] and ii) the tumour dynamics 
[(with genetic instability and accumulations of mutations throughout tumour 
development (Sequist et al., 2011)]. In addition, an evolutive adaptation of cancer cells to 
drugs has been proposed as a mechanism that promotes drug resistance [reviewed in 
(Gerlinger and Swanton, 2010)]. The most common cause for acquisition of cancer drug 
resistance is the expression of energy-dependent transporters (or drug efflux pumps), that 
detect some anticancer drugs and carry out the efflux of such drugs from the cancer cells. 
Since the drug efflux transporters are not specific for a designated substrate, cells that 
overexpress drug efflux  pumps such as P-glycoprotein (P-gp) are resistant to various 
drugs, a phenotype known as multidrug resistance (MDR) [reviewed in (Gottesman et al., 
2002)]. However, several other mechanisms of drug resistance are known to occur, such 





repair or mutations in drug targets [reviewed in (Gottesman et al., 2002; Fojo, 2007; 
Borst, 2012)]. Table 1.1 summarizes the most common mechanisms of drug resistance.  
 





















In this work, we will review the current knowledge on the role of miRNAs in drug 
resistance. 
 
2. Anticancer drugs may affect cellular miRNA expression 
miRNA expression has been shown to be altered by anticancer drugs. For example,  a 
panel of 60 human cancer cell lines (NCI-60) which has been used to screen more than 
100.000 compounds for their anticancer potential, has been profiled for mRNA and 
protein expression, mutational status, DNA copy number, chromosomal alterations (Boyd 
and Pauli, 1995) and miRNA expression (Blower et al., 2007; Gaur et al., 2007b). These 
studies have shown a correlation between the expression pattern of some miRNAs and the 
growth inhibitory pattern of certain drugs, which may indicate a role for such miRNAs in 
drug response (Blower et al., 2007). 
Other studies have also shown that anticancer drugs affect miRNAs expression (Rossi et 
al., 2007; Flamant et al., 2010; Gmeiner et al., 2010). Nevertheless, the results cannot be 
analysed straightforward as the observed alterations are due to specific characteristics of 
the experimental design such as drug concentration, time of exposure to the drug or the 




type of cells in which the anticancer drugs were tested. Therefore, the precise function of 
each miRNA might not be easy to assess and still needs extensive work. 
 
3. MicroRNAs involved in cancer drug response: drug sensitivity and drug 
resistance 
The fact that various cancer drugs affect cellular miRNAs expression indicates that 
miRNAs may be important regulators of mechanisms involved in treatment outcome. 
Nevertheless, it is not known if those miRNAs have a function in drug response or in drug 
resistance, or both. In order to confirm this, functional studies, either by overexpressing or 
silencing the expression of such miRNAs in cell lines have been performed (Table 1.2). 
 
































































































































































































































































































































































































miR‐152    ↑   sensitizes ovarian cancer cells to CDDP (Xiang et 
al., 2013b) 
DNMT1 





































































miR‐199a‐3p  ↑  sensitizes HCC cells to DOX (Fornari et al., 2010)  mTOR 
















































































































































































































































































































































As can be seen by Table 2, a great number of miRNAs have been shown to modulate drug 
response. Some of them have been described more frequently than others, granting them 




miR-21 is overexpressed in almost all types of tumors (Volinia et al., 2006) and it is 
generally accepted as being an “oncomiR”. Its expression is often associated with drug 
resistance, firstly described when downregulation of miR-21 sensitized 
cholangiocarcinoma cell lines to gemcitabine (Meng et al., 2006). miR-21 has been shown 
to regulate the translation of several mRNAs such as PTEN, Bcl-2 or PDCD4 (programmed 
cell death 4), all of which play important roles in cellular mechanisms such as cellular 
growth, apoptosis, invasion and cell cycle. The miR-21 involvement in drug resistance has 
been demonstrated in several cancer cell types such as breast (Wang et al., 2011c), colon 
(Valeri et al., 2010), gastric (Xiang et al., 2013a), prostate (Li et al., 2009a), among others, 
and it has also been shown to modulate resistance to several drugs, from the conventional 
chemotherapies such as 5-fluorouracil (Tomimaru et al., 2010), cisplatin (Chen et al., 





2009), gefitinib (Garofalo et al., 2012b) or trastuzumab (Gong et al., 2011). Although miR-
21 expression is most often associated with cancer drug resistance, its expression can 
modulate the sensitivity of cytotoxic drugs in opposite directions depending on the 
compound class, indicating that different mechanisms determine toxic and protective 
effects (Blower et al., 2008). In fact, miR-21 ectopic expression has been associated with 
chemosensitivity to cisplatin in tongue squamous cell carcinoma cell lines (Yu et al., 
2010). Another study has shown a non-canonical mechanism of mRNA regulation by miR-
21. Indeed, it has been demonstrated that miR-21 binds the 3’UTR region of Bcl-2 mRNA 
causing an increase in the expression of Bcl-2 protein and consequent gemcitabine 
resistance in pancreatic cancer cells (Dong et al., 2011). miR-21 has also been shown to be 
involved in resistance to doxorubicin and etoposide by induction of autophagy and 
inhibition of miR-21 expression increased the sensitivity of leukemia cells to the above 
mentioned drugs (Seca et al., 2013). 
 
3.2 miR-34a 
The family of miR-34, which includes miR-34a, miR-34b and miR-34c, is transcriptionally 
activated by p53 (Gaur et al., 2007b). This prompts the evaluation of miR-34 expression in 
cancer cells since p53 is a pivotal tumor-suppressor protein often deregulated in cancer. In 
fact, miR-34a has been shown to be downregulated in many p53 deficient cell lines and 
this downregulation was associated with drug resistance (Fujita et al., 2008; Ji et al., 
2008; Kojima et al., 2010). Furthermore, ectopic expression of miR-34a was shown to 
sensitize prostate cancer cell to camptothecin (Fujita et al., 2008), bladder cancer cells to 
cisplatin (Vinall et al., 2012) or breast cancer cells to doxorubicin (Li et al., 2012b). miR-
34a has been shown to target several proteins known to be regulated by p53 (Wong et al., 
2011). SIRT1 (a protein deacetylase which is involved in apoptosis), Bcl-2 (an anti-
apoptotic protein), cyclin D1 and Cdk6 (involved in cell cycle control) have all been shown 
to be direct or indirect targets of miR-34a (Fujita et al., 2008; Ji et al., 2008; Vinall et al., 
2012). The fact that miR-34a inhibits the expression of these proteins underlies its effect 
in sensitizing different cancer cell types to various cancer drugs. However, a different 
study has shown that miR-34a targeted Bcl-2 mRNA, thus decreasing its expression, but 
that its ectopic expression was associated with increased resistance to docetaxel in breast 
cancer cells through an unidentified mechanism (Kastl et al., 2012). 
Two recent papers have described two other targets for miR-34a. Notch1 signaling may 
contribute to cancer chemoresistance (Gu et al., 2010) and miR-34a overexpression 
sensitized breast cancer cells to doxorubicin by targeting Notch1 (Li et al., 2012b). MAGE-
A, which is aberrantly expressed in many cancers (Kasuga et al., 2008), was also shown to 




be a target of miR-34a; in addition, miR-34a overexpression sensitized medulloblastoma 
cells to both cisplatin and mitomycin C (Weeraratne et al., 2011). 
 
3.3 miR-221/222 
miR-221/222 are encoded in the X chromosome and share the same seed sequence 
between them (Garofalo et al., 2012a). They are commonly regarded as “oncomiRs” as 
they target several tumor suppressor proteins such as Apaf-1, p27Kip1, PTEN or TIMP3 
(Garofalo et al., 2012a). In fact, it has been shown that by targeting these mRNAs, miR-
221/222 could increase resistance to TRAIL and gefitinib in non-small cell lung cancer 
(NSCLC) cells (Garofalo et al., 2008; Garofalo et al., 2009; Garofalo et al., 2012b). miR-
221/222 has also been shown to target and downregulate ERα expression, thus being 
partially responsible for resistance to tamoxifen (Zhao et al., 2008). Therefore, 
downregulation of miR-221/222 sensitized breast cancer cells to tamoxifen-induced cell 
growth arrest and apoptosis (Zhao et al., 2008). Another study has shown that p27Kip1 is 
also decreased by miR-221/222 in tamoxifen resistant cells (Miller et al., 2008). Other 
studies showed that ectopic expression of miR-221/222 conferred resistance to fulvestrant 
in breast cancer cells through the deregulation of multiple oncogenic signaling pathways 
that involved β-catenin activation and repression of TGF-β (Rao et al., 2011). 
Interestingly, miR-222 ectopic expression has been also shown to sensitize HCT-8 and 
HCT116 resistant gastric cancer cells to oxaliplatin. miR-222 overexpression decreased 
ADAM-17 expression, thus decreasing EGFR activation and TGF-α shedding, which in 
turn reduces P-gp and MRP1 efflux pump expression (Xu et al., 2012c). 
 
3.4 miR-451 
miR-451 is involved in erythropoiesis, being essential for maintenance and/or late-stage 
maturation of committed erythroid precursors (Dore et al., 2008). Its association with 
cancer drug resistance was first described in breast cancer cells resistant to doxorubicin 
which presented a clear upregulation of P-gp protein, a known drug efflux transporter. 
Ectopic expression of miR-451 targeted MDR1 mRNA and thus sensitized these cells to 
doxorubicin (Kovalchuk et al., 2008). miR-451 has been also shown to sensitize both 
chronic myeloid leukemia (CML) and glioblastoma cells to imatinib, although without an 
identified target (Gal et al., 2008; Liu et al., 2012b). Moreover, miR-451 has been shown 
to be involved in the inhibition of colon cancer stem cells (CSCs) (Bitarte et al., 2011). By 
binding the migration inhibitory factor (MIF) mRNA and hampering its translation, as 
well as indirectly controlling COX-2 expression, miR-451 regulates the Wnt signaling 
activity [which defines colon CSCs (Vermeulen et al., 2010)] sensitizing colon CSCs to 





stabilizes key proteins involved in signal transduction and cell cycle regulation (Zannis-
Hadjopoulos et al., 2008)] as a direct target of miR-451 that is involved in tamoxifen 
resistance in breast cancer cells (Bergamaschi and Katzenellenbogen, 2012). Additionally, 
it has been shown that miR-451 was downregulated in NSCLC tissue, compared to non-
cancerous adjacent tissue and that ectopic expression of miR-451 sensitized lung cancer 
cells to cisplatin (Bian et al., 2011). 
 
4. Regulation of drug response pathways by microRNAs 
4.1 Regulation of apoptosis 
miRNAs have been shown to target one or simultaneously various mRNAs involved in the 
core apoptotic signaling, acting both as anti-apoptotic and pro-apoptotic molecules 
[reviewed in (Lima et al., 2011)]. Moreover, various miRNAs which target apoptosis 
related proteins, particularly of the intrinsic apoptotic pathway, have already been 
described to be associated with drug response. The anti-apoptotic Bcl-2 is targeted by 
several miRNAs and this has been shown to modulate the response of different cancer 
cellular models to various drugs. For example, miR-15a, -15b, -16, -34a, -129, -181b, -
200bc/429cluster, -497 and -1915, all of which downregulate Bcl-2 expression, have been 
related to the decrease of resistance to tamoxifen in breast cancer cells (Cittelly et al., 
2010a) or to other drugs such cisplatin, doxorubicin, etoposide, docetaxel, vincristine, 
gemcitabine and 5-fluorouracil in colon, gastric, breast or lung cancer cells (Ji et al., 2008; 
Xia et al., 2008; Zhu et al., 2010; Kastl et al., 2012; Zhu et al., 2012a; Zhu et al., 2012b; 
Karaayvaz et al., 2013) (Xu et al., 2013). In addition, miR-181a downregulation and 
consequent upregulation of Bcl-2 was shown to confer resistance to cytarabine in acute 
myeloid leukemia cells (Bai et al., 2012) while its over-expression sensitized CML cells to 
daunorubicin by targeting Bcl-2 (Li et al., 2012a). Moreover, miR-21 which has been 
shown to directly bind to the 3'UTR of Bcl-2 mRNA, increasing its expression, caused 
gemcitabine resistance in pancreatic cancer cells (Dong et al., 2011).  
Another anti-apoptotic Bcl-2 family member is Mcl-1, which has been found to be directly 
targeted by miR-101, -148b, -153, -193a, -558a-5p, -582-5p, -661, -876-3p, -886-3p and -
892b in a study aiming at identifying miRNAs modulators of colon cancer cells sensitivity 
to ABT-263 (Lam et al., 2010). Another study has also shown the ability of miR-101, found 
down-regulated in hepatocellular carcinoma (HCC), to sensitize these tumor cells to 
chemotherapeutic drug–induced apoptosis (Su et al., 2009). Moreover, and at least in part 
through the modulation of apoptosis via targeting Mcl-1, miR-135 a/b have been suggested 
to play a role in the development of cisplatin resistance in lung cancer cells (Zhou et al., 
2013).   




In addition, the downregulation of Bcl-w (antiapoptotic Bcl-2 family protein) by miR-195, 
-205 and -214 has been described to modulate resistance to cisplatin, doxorubicin, 
docetaxel or 5-fluorouracil in cervical, colon, hepatocellular or prostate cancer cells 
(Bhatnagar et al., 2010; Yang et al., 2012e; Qu et al., 2013; Wang et al., 2013b). Moreover, 
inhibition of Bcl-xL (anti-apoptotic Bcl-2 family member) by let7c has been found to 
sensitize HCC cells to apoptosis induced by sorafenib (Shimizu et al., 2010). 
On the other hand, the pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) is targeted by miR-
125b. This has been shown to increase resistance in breast cancer cells to paclitaxel and 
gemcitabine (Zhou et al., 2010; Liu et al., 2013c), of ovarian cancer cells to cisplatin (Kong 
et al., 2011) and of leukemia cells to doxorubicin (Zhang et al., 2011a). 
Likewise, the regulation of the BH3-only protein, Bim, by miRNAs also plays a role in drug 
response. Indeed, the blockage of Bim expression by miR-17 in lung cancer cells caused 
resistance to AZD6244 (a small molecule inhibitor of the MEK pathway) (Dai et al., 2011). 
Moreover, miR-17~92 cluster, which targets Bim and PTEN, has been shown to confer 
resistance to doxorubicin and to etoposide in mantle cell lymphoma (Rao et al., 2012). In 
addition, miR-30b and -30c were shown to modulate the resistance of lung cancer cells to 
gefitinib (Garofalo et al., 2012b) while miR-494 induced TRAIL resistance in NSCLC, all 
through a downregulation of Bim (Romano et al., 2012). Moreover, miR-10b expression 
(which also downregulates Bim) was described as a potential indicator of chemosensitivity 
to 5-fluorouracil-based chemotherapy regimens in colorectal cancer (Nishida et al., 2012). 
Other apoptotic proteins are known to be regulated by miRNAs, altering drug response of 
cancer cells. For example, by targeting caspase-3, let-7a suppressed HCC death induced by 
doxorubicin, IFN-γ and paclitaxel (Tsang and Kwok, 2008). Also, the expression of miR-
106a, which targets caspase-7 (and also BCL10) has been shown to be associated with 
paclitaxel resistance in ovarian cancer cells (Huh et al., 2013). Furthermore, by 
downregulating the apoptotic peptidase activating factor-1 (APAF-1), miR-221 and -222 
increased lung cancer cells resistance to gefitinib (Garofalo et al., 2012b). 
Finally, the most potent member of the inhibitor of apoptosis family, XIAP, is targeted by 
miR-200bc/429 cluster (all of which, interestingly, also target Bcl-2) and this seems to be 
associated with increased sensitivity of gastric and lung cancer cells to cisplatin, 
doxorubicin, vincristine and etoposide (Zhu et al., 2012a). 
 
4.2 Regulation of p53 levels 
The p53 pathway is one of the major players in the regulation of cellular response to drugs. 
P53, considered the guardian of the genome, may initiate DNA repair, cell-cycle arrest, 
senescence and, importantly, apoptosis [reviewed in (Vazquez et al., 2008)]. Several miRs 





In particular, miR-25, -30d and -504 have been shown to directly target p53. Their 
overexpression reduces p53 protein levels impairing p53 functions, such as p53-mediated 
transcriptional activation, apoptosis, and cell-cycle arrest as well as conferring resistance 
to etoposide induced cell death (Hu et al., 2010c; Kumar et al., 2011). In addition miR-375 
has also been shown to target and downregulate p53 expression, affecting the response to 
ionizing radiation and etoposide treatment. In fact, the expression of miR-375 
desensitized AGS cells to ionizing radiation and etoposide, abrogating the cell cycle arrest 
and apoptosis after DNA damage (Liu  et al., 2013). 
There are other miRNAs such as miR-122 and miR-630 that have been shown to affect p53 
stability and activity, leading to alterations in drug sensitivity (Fornari et al., 2009; 
Galluzzi et al., 2010). Besides the miRNAs that directly or indirectly regulate p53 
expression, there are also miRNAs that are regulated by p53 and are involved in drug 
response, such as miR-34 (Bommer et al., 2007) and miR-519 (Fornari et al., 2012). 
 
4.3 Regulation of autophagy 
The role of autophagy in drug response is complex and not fully understood but several 
studies have shown that autophagy is involved in chemoresistance. 
miR-30a is one of the miRNA which is frequently found associated with autophagy. It 
targets Beclin-1, resulting in decreased autophagic activity. Through the inhibition of 
Beclin-1 expression, miR-30a regulated autophagy induced by rapamycin in breast and 
lung cancer cells (Zhu et al., 2009). In addition, in a CML cell line and in CML 
stem/progenitor cells, overexpression of miR-30a decreased Beclin-1 and ATG5 
expression (and subsequently autophagy), enhancing imatinib-induced apoptosis (Yu et 
al., 2012a; Yu et al., 2012b). Moreover, in a study using cell lines and animal models, 
cisplatin or taxol treatment were found to increase autophagy but to decrease the levels of 
miR-30a. Importantly, the inhibition of Beclin-1-mediated tumor cell autophagy which 
was possible following the increase in miR-30a levels, significantly promoted cisplatin-
induced tumor cell apoptosis (Zou et al., 2012b). 
miR-101 was identified as potent inhibitor of autophagic flux in MCF-7 breast cancer cells. 
This miRNA is described to directly target STMN1, RAB5A and ATG4D, blocking 
autophagy, and to increase the cytotoxicity of 4-hydroxytamoxifen in breast cancer cells 
(Frankel et al., 2011). 
miR-199a-5p was found to be significantly reduced in HCC patients treated with cisplatin-
based chemotherapy and in human HCC cell lines following cisplatin treatment. This 
cisplatin-induced downregulation of miR-199a-5p resulted in drug resistance. In addition, 
the decrease in miR-199a-5p has resulted in enhanced autophagy activation by targeting 
ATG7 (Xu et al., 2012e).  




Finally, through microRNA profiling, miR-375 was found to be upregulated in DOX-
induced senescent K562 (CML) cells. This upregulated expression was found to be 
associated with decreased expression of 14-3-3ζ and SP1 genes and with initiation of 
autophagy (Yang et al., 2012d). 
 
4.4 Regulation of DNA damage response 
The mechanisms involved in DNA damage response (DDR) are mediated through several 
proteins including those acting as DNA damage sensors (such as H2AX, BRCA1), as signal 
transducers [such as ATM (ataxia telangiectasia mutated) and ATR (ATM-Rad3-related)] 
and as effectors [including DNA repair, cell-cycle checkpoint (G1/S, intra-S and G2/M) 
and apoptosis mechanisms] [reviewed in (Green and Lin, 2012)]. Several reports have 
already described miRNAs which regulate DDR and DNA repair (Lal et al., 2009; Pothof 
et al., 2009; Bhatnagar et al., 2010; Hu et al., 2010a).  
miR-24 was found to downregulate H2AX, suppressing DNA repair in terminally  
differentiated blood cells. miR-24 upregulation, in post-replicative cells, reduces H2AX 
and renders cells vulnerable to DNA damage (Lal et al., 2009). Another study has shown 
that miR-24 overexpression was associated with decreased expression of H2AX and 
decreased DDR upon etoposide treatment in highly differentiated CD8+ T cells (Brunner et 
al., 2012). Overexpressing miR-24 in breast cancer cells increased sensitive to cisplatin 
through direct targeting H2AX (Srivastava et al., 2011). In addition, in an osteosarcoma 
cell line, miR-138 was also found to enhance cellular sensitivity to cisplatin and 
camptothecin by directly targeting H2AX gene (Wang et al., 2011b). In another study with 
cisplatin-resistant human NSCLC cells (A549/DDP), it was shown that the upregulation of 
miR-138 increased the sensitivity of these cells to cisplatin.  In that same study, the 
excision repair cross-complementation group 1 (ERCC1) was also found to be negatively 
regulated by miR-138, with its levels being inversely correlated with the levels of miR-138 
in A549/DDP cells (Tao et al., 2011). 
miR-182 has been described to target BRCA1. In breast cancer cells, miR-182 was shown 
to mediate BRCA1 downregulation, affecting DNA repair (Moskwa et al., 2011). 
ATM was shown to be directly targeted by miR-18a, with their expression being inversely 
correlated in rectal tumor tissues. The repair of DNA damage induced by etoposide was 
inhibited by miR-18a, leading to increased apoptosis and accumulation of DNA damage 
(Wu et al., 2013a). miR-181a/b was also shown to directly target ATM and to sensitize 
breast cancer cells to PARP inhibitors (Bisso et al., 2013). 
The mismatch repair (MMR) system is involved in DNA damage recognition and repair. 
miR-21 was shown to target the core MMR complex, human mutS homolog 2 (hMSH2) 





significantly reduced sensitivity to 5-fluorouracil (Valeri et al., 2010). DNA repair protein 
RAD51 and the trans-lesion synthesis DNA polymerase REV1 are transcriptionally 
regulated by miR-96, which directly targets the 3’UTR of REV1 and the coding region of 
RAD51. Overexpression of miR-96 increases sensitivity to PARP inhibitor AZD2281 in 
vitro and to cisplatin both in vitro and in vivo (Wang et al., 2012d). Matrix extracellular 
phosphoglycoprotein (MEPE) is a cofactor of CHK1 that protects cells from DNA damage-
induced killing (Zhang et al., 2010c). miR-376a was shown to target MEPE, reducing G2 
arrest and sensitizing cervical and liver cancer cells to camptothecin and etoposide (Sheng 
et al., 2013). 
It has been shown that c-Myc overexpression causes DNA damage (Dominguez-Sola et al., 
2007). miR-34c has been shown to target and repress c-Myc upon etoposide induced DNA 
damage, inhibiting DNA synthesis as well as blocking cells in S-phase, thus preventing 
replication of damaged DNA (Cannell et al., 2010). 
 
4.5. Regulation of cancer stem-like cells and epithelial to mesenchymal 
transition 
CSCs are thought to have a major role in tumor proliferation, invasion or metastasis. 
Epithelial to mesenchymal transition (EMT) is a process that encompasses a transition 
from a cobblestone phenotype to a fibroblastic phenotype, together with acquisition of 
increased cell motility and invasion [reviewed in (Thiery et al., 2009)]. These cellular 
alterations are accompanied by molecular adjustments including the decreased expression 
of E-cadherin and β-catenin and increased expression of vimentin, fibronectin or smooth-
muscle actin [reviewed in (Thiery and Sleeman, 2006)]. Current data suggests that the 
attainment of the EMT phenotype and the appearance of CSCs share biological alterations 
and cooperate in the development of cancer metastasis, recurrence, and chemoresistance 
(Mani et al., 2008; Hollier et al., 2009). 
Analysis of miRNAs that regulate stem cell function and their association with the 
response to chemotherapy in esophageal cancers pointed to miR-200c, a miRNA known to 
regulate stem cell function, as being involved in chemoresistance to cisplatin through 
directly interaction with PPP2R1B, a protein that inhibits tumor invasiveness and is 
involved in Akt pathway (Hamano et al., 2011). In addition, miR-145 was shown to directly 
target the 3’UTR of Oct4 and Sox2, two know stem cell markers. Overexpression of miR-
145 in glioblastoma (GBM) CSCs reduced the expression of these factors as well as of other 
stemness genes, including Nanog, c-Myc, and of the oncogene Bmi-1. It also reduced 
MDR1 and ABCG2 proteins, sensitizing these cells to both cisplatin and temozolomide. All 
these results demonstrate that miR-145 is a key hub in the stemness network of GBM 
CSCs (Yang et al., 2012f). 




miR-125a/b has been shown to directly target and decrease both Mcl-1 and ALDH1A3, a 
cancer stem cell marker (Douville et al., 2009). ALDH1-positive cells from the HT29 colon 
cancer cell line were resistant to paclitaxel and this resistance could be overcome by 
overexpression of miR-125a/b (Chen et al., 2013a). Intriguingly, miR-125b overexpression 
was shown to increase CSC population and to confer resistance to taxol and gemcitabine in 
human breast epithelial cells by targeting Bak1 (Liu et al., 2013c). In another study, 
docetaxel-resistant pancreatic cells presented various stem cell markers as well as EMT 
phenotype. Transfection of either miR-200c or miR-205 could revert the phenotype and 
sensitize these cells through directly targeting ZEB1 and ZEB2 (zinc finger E-box–binding 
homeobox 1 and 2) (Puhr et al., 2012). ZEB1 was also shown to be directly targeted by 
miR-591. Moreover, overexpression of miR-591 decreased cell proliferation and migration 
and sensitized ovarian cancer resistant cells to paclitaxel (Huh et al., 2013). 
Overexpression of miR-216a/217 was shown to directly target PTEN and SMAD7 and thus 
activate both TGF-β and PI3K/Akt pathways. This overexpression induced EMT and 
increased the stem-like cell population conferring resistance to sorafenib in HCC cells (Xia 
et al., 2013a). 
E-cadherin, known to be involved in EMT, is directly targeted by miR-23a. In NSCLC cell 
lines, overexpression of miR-23a led to increased resistance to gefitinib and increased 
EMT phenotype (Cao et al., 2012). Bmi1 is another protein reported to be involved in EMT 
and stem cell self-renewal (Song et al., 2009b; Yang et al., 2010). miR-15b and -200b have 
been shown to directly target Bmi1, revert EMT phenotype, suppress motility and 
migration and sensitize tongue squamous cell carcinoma resistant cells to cisplatin (Sun et 
al., 2012). Other studies have shown the involvement of miR-200 family in the regulation 
of EMT and drug resistance. In bladder cancer cells, overexpression of miR-200b and -
200c inhibited cell migration and sensitized cells to cetuximab by directly binding ZEB1, 
ZEB2 and ERRFI-1 (Adam et al., 2009). In another study, re-expression of miR-200b in 
gemcitabine resistant pancreatic cancer cells reverted the EMT phenotype and sensitized 
cells to gemcitabine (Li et al., 2009c). Additionally, miR-200c was shown to directly target 
other mesenchymal genes such as class III β-tubulin (TUBB3). Ectopic expression of miR-
200c sensitized endometrial Hec50 cancer cells to paclitaxel and vincristine but not to 
doxorubicin or cisplatin, indicating that targeting TUBB3 is a major mechanism through 
which miR-200c restores sensitivity to microtubule-binding chemotherapeutic agents 
(Cochrane et al., 2009). 
In tamoxifen resistant cells, re-expression of miR-375 sensitizes cells to tamoxifen, 
inhibiting invasion and reverting EMT-like properties. miR-375 was shown to directly 





the mesenchymal markers ZEB1 and SNAI2, indicating that the involvement of miR-375 
in EMT could, at least in part, be via targeting MTDH (Ward et al., 2013). 
 
4.6 Regulation of drug efflux 
By regulating genes involved in drug efflux, several miRNAs have been shown to play a 
role in drug resistance. In particular, several of these miRNAs are directly or indirectly 
related with MDR1/P-gp expression, one of the main contributors to the MDR phenotype 
[reviewed in (Lopes-Rodrigues et al., 2013)]. 
Various miRNAs have been described to directly target the 3’-UTR of the MDR1 mRNA. 
An inverse correlation between the expression of such miRNAs and MDR1 mRNA and P-
gp is observed. Indeed, overexpression of miR-451, -331-5p or -27a, which target MDR1/P-
gp, has increased sensitivity of breast cancer and leukemia cells to doxorubicin (Kovalchuk 
et al., 2008; Feng et al., 2011).  On the other hand, the down-regulation of miR-298 in 
breast cancer cells increased P-gp expression and resistance to doxorubicin. Importantly, 
miR-298 expression has been proposed as potential predictor of doxorubicin 
chemoresistance in human breast cancer (Bao et al., 2012).  
Other miRNAs indirectly regulate MDR1/P-gp expression, by targeting mRNAs involved 
in MDR1 gene activation. The expression of such miRNAs has also been associated with 
drug response. Indeed, increased miR-21 caused a decrease in the levels of the tumor 
suppressor protein PDCD4, which was found to be associated with increased translation of 
several transcripts, including MDR1. miR-21 downregulation enhanced multidrug 
sensitivity in MCF-7 cells (Bourguignon et al., 2009). Moreover, the downregulation of 
miR-130a in cisplatin resistant SKOV3 ovarian cancer cells caused an indirect inhibition of 
MDR1 mRNA and of P-gp expression and reverted resistance to cisplatin (Yang et al., 
2012c). In addition, let-7 affected acquired resistance of ovarian cancer cells to taxanes by 
targeting IMP-1, resulting in MDR1 mRNA destabilization (Boyerinas et al., 2012). 
Interestingly, in ovarian and cervical cancer cells, miR-27a and -451 (previously referred 
as direct MDR1/P-gp regulators) also seem to be activators of P-gp expression (Zhu et al., 
2008). Indeed, antagomirs of miR-27a or -451 decreased MDR1 mRNA and P-gp 
expression, increasing sensitivity to drugs which are P-gp substrates (Zhu et al., 2008). 
In addition to the above referred miRNAs, regulating P-gp expression at a post-
transcriptional level, some miRNAs have been proposed to regulate MDR1 expression, at a 
transcriptional level, by interfering with its promoter region, and others through unknown 
mechanisms [reviewed in (Toscano-Garibay and Aquino-Jarquin, 2012) and (Lopes-
Rodrigues et al., 2013)]. miR-138 upregulation in promyelocytic leukemia cells reverted 
the MDR phenotype by downregulating P-gp (Zhao et al., 2010). In addition, 
downregulation of miR-27a decreased P-gp expression, possibly reverting drug resistance 




in esophageal squamous cells and gastric cancer cells (Zhang et al., 2010a; Dong et al., 
2011). miR-200c was down-regulated in breast cancer patients which were non-
responders to neoadjuvant chemotherapy (compared to responders) and in doxorubicin-
resistant human breast cancer cells MCF-7/ADR (compared to parental MCF-7 cells). 
miR-200c restoration in MCF-7 cells reduced MDR1 mRNA and P-gp and increased 
sensitivity to epirubicin (Chen et al., 2012b). The overexpression of miR-122, a liver 
specific miRNA frequently downregulated in HCC, could modulate the sensitivity of HCC 
cells to drugs through the downregulation of MDR related genes including MDR1 and 
MRP (Xu et al., 2011b). 
In addition to MDR1/P-gp, the regulation of other efflux proteins by miRNAs has also 
been associated with drug response/resistance. For example, miR-181a, -328, -519c and -
520h target BCRP/ABCG2. This has been shown to modulate colon and breast cancer cells 
sensitivity to mitoxantrone, 5-fluorouracil or hydroxycamptothecin (Pan et al., 2009b; To 
et al., 2009; Xu et al., 2012f; Jiao et al., 2013).  
miR-326, which was downregulated in etoposide resistant MCF-7 cells (MCF-7/VP) and in 
a panel of advanced breast cancer tissues, negatively correlated with MRP1/ABCC1 levels. 
miR-326 overexpression in MCF-7/VP cells sensitized cells to etoposide and doxorubicin 
(Liang et al., 2010).  
Finally, miR-297 targets MRP2/ABCC2 and was down-regulated in a panel of human 
colorectal carcinoma tissues, as well as in the oxaliplatin resistant cell line HCT116/L-OHP 
(comparing with its parental cells). The ectopic expression of miR-297 in MDR colorectal 
carcinoma cells sensitized cells to anticancer drugs in vitro and in vivo (Xu et al., 2012b). 
 
4.7 Regulation of drug metabolism 
Drugs are metabolized mainly by enzymes of the cytochrome P450 (CYP) family, which 
may be post-transcriptionally regulated by miRNAs. CYP members are overexpressed in a 
wide range of cancers, metabolizing cancer drugs and probably conferring drug resistance 
(Murray et al., 1997). The first miRNA found to be associated with a CYP member was 
miR-27b, which was shown to directly target CYP1B1 in breast cancer cells (Tsuchiya et al., 
2006).  miR-27b has also been shown to directly bind and regulate CYP3A4 expression 
(Pan et al., 2009a). Other CYP members have since been found to be targets of miRNAs. 
CYP24 is targeted by miR-125b (Komagata et al., 2009), CYP2E1 by miR-378 (Mohri et 
al., 2010), CYP1A1 by miR-892a (Choi et al., 2012) and CYP2J2 by let-7b (Chen et al., 
2012a). Besides directly targeting CYP proteins, miRNAs have been shown to target 
transcription factors that regulate the expression of a variety of drug-metabolizing 
enzymes, such as Pregnane X receptor (PXR). For example, miR-148a directly targets PXR 





5. Non-genetic acquisition of microRNAs via microvesicles and exosomes 
A possible association between the number of exosomes and cancer drug resistance has 
been described [reviewed in (Camussi et al., 2010; Muralidharan-Chari et al., 2010)]. In 
fact, chemoresistant cancer cells were shown to release more microvesicles than 
chemosensitive cancer cells (Safaei et al., 2005). In addition, it is known that miRNAs 
may be included in exosomes and transfer drug resistance to other (Jaiswal et al., 2012a). 
A recent study has shown that microvesicles from P-gp overexpressing drug resistant cells 
can selectively package some miRNAs into microvesicles, which upon release on the 
recipient drug sensitive cells can confer MDR by “retemplating” these cells, reflecting the 
donor resistant phenotype (Jaiswal et al., 2012a; Jaiswal et al., 2012b). 
Interestingly, the transfer of miR-21-mediated chemoresistance in pancreatic 
adenocarcinoma cells has very recently been shown to occur via cell-to-cell contact 
involving the Systemic RNA Interference-defective-1 Transmembrane Family Member 1 
(SIDT1) (Elhassan et al., 2012). 
 
6. MicroRNAs polymorphisms associated with drug resistance  
miRSNPs or miRs-polymorphisms have been described as a novel class of functional 
polymorphisms, usually present at (or near) a miRNA binding site of functional genes and 
in genes involved in miRNA biogenesis. These polymorphisms may affect gene expression 
by interfering with a miRNA function. Therefore, this can lead to drug 
resistance/sensitivity depending on the function of the targeted mRNA that presents the 
polymorphism [reviewed in (Mishra et al., 2008; Zhang and Dolan, 2010)]. 
In particular, a miR-200b/200c/429-binding site polymorphism in the 3´-UTR region of 
AP-2alpha gene (a transcription factor which regulates several genes involved in cell 
proliferation and apoptosis) was found to associate with resistance to cisplatin in 
endometrial cancer cells (Wu et al., 2011). 
miR-24 expression targeting the common drug target DHFR (dihydrofolate reductase) has 
been shown to regulate cellular proliferation. Indeed, miR-24 SNP has been shown to 
interfere with miR-24 function, to increase DHFR mRNA and protein expression and 
resistance to methotrexate resistance (Mishra et al., 2007a; Mishra et al., 2008; Mishra et 
al., 2009; Zhang and Dolan, 2010).  
Moreover, for the let-7 family of miRNAs, which binds to and regulates the expression of 
KRAS genes, a polymorphism in the let-7 complementary-binding site (lcs6) of the 3’-UTR 
of KRAS gene has been described. The presence of this polymorphism has been shown to 
increase KRAS expression in vitro (Chin et al., 2008). Interestingly, let-7 lcs6 
polymorphism was shown to predict response in wild-type KRAS patients with metastatic 




colorectal cancer treated with cetuximab monotherapy, and may therefore be considered 
as a predictive marker of cetuximab efficacy in this context (Zhang et al., 2011b). 
miRNA polymorphic variants have also been hypothesized as useful predictors of clinical 
outcome in metastatic colorectal cancer patients treated with the combination of 5-
fluorouracil and irinotecan (Boni et al., 2011). In addition, studies in cervical cancer have 
shown that, in the absence of information on human papillomavirus infection, the tumor 
necrosis factor-alpha-induced protein 8 (TNFAIP8)-rs11064 SNP may affect the affinity of 
miR-22 binding to the 3'-UTR of TNFAIP8, regulating its expression. This may contribute 
not only for the risk of developing cervical cancer but also, the increased in TNFAIP8 
protein expression may help predict platinum resistance and clinical outcomes in cervical 
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The role of miRNAs in cancer is well documented. In fact, a wide range of miRNA 
signatures have been documented in different leukemias and the particular function of 
some miRNAs in both CML and AML has also been addressed. Nonetheless, the function 
of miRNAs in leukemia drug resistance and drug response in not fully understood. 
 
Thus, the aims of the present work were: 
 
1. Further understand the role of miR-21 in CML cell lines. 
 
The role of miR-21 in CML is not fully understood. To address this issue, the expression 
of miR-21 was downregulated with antimiRs in two CML cell lines (K562 and KYO-1). 
Cellular viability along with cellular processes such as cell proliferation, cell cycle, 
programmed cell death and autophagy were assessed. Further investigation of an 
associated autophagy mechanism was carried out. Expression of autophagy-related 
proteins (such as Vps34, Beclin-1 and LC3) was analysed by Western blotting, together 
with the presence of autophagosomes by fluorescence microscopy. Cellular ultra-structure 
was analysed by electron microscopy in order to confirm the presence of autophagic 
structures. Furthermore, the effect of the etoposide and doxorubicin on both cell lines was 
also analysed, in order to verify if downregulation of miR-21 increased cellular response to 
these cytotoxic drugs. 
 
 
2. Investigate if miR-21 is present in various extracellular vesicles from CML cells. 
 
The discovery that different types of extracellular vesicles (EVs) are secreted from cells, 
and that they can carry cellular content (such as proteins, mRNAs or miRNAs) which can 
then be incorporated into neighboring cells, has recently increased the scientific interest in 
these cellular structures. In particular, it has become evident that EVs may carry miRNAs 
that are responsible for drug resistance, from resistant to sensitive cells. However, it is not 
known if miR-21 is transported in EVs “shed” from CML cells, and moreover if different 
types of EVs carry different levels of miR-21. To address this issue, EVs from K562 (CML) 
cells were extracted using four different protocols, in order to isolate different types of 









3. Study the role of miR-128 in an AML cell line. 
 
miR-128 was shown to be associated with AML in several miRNA profiles but none of 
them exploited the functional mechanism that could explain this association. In order to 
address this question, overexpression of miR-128 was carried out in an AML cell line 
(HL60). Following miR-128 overexpression, cellular viability and sensitivity to 
doxorubicin and etoposide was assessed. Several cellular processes, such as cell cycle, cell 
proliferation, apoptosis, autophagy and DNA damage were studied. Moreover, miR-128 
expression was analysed in AML bone marrow samples  in order to confirm the levels of 























  CHAPTER II.  
 












The experimental results obtained in the scope of this thesis were organized in the 
form of research articles presented in this chapter. Thus, Aim 1 was addressed in Article 1, 

































ARTICLE 1. TARGETING MIR-21 INDUCES AUTOPHAGY AND CHEMOSENSITIVITY 
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Within the last years, extracellular vesicles (EVs) have emerged as important mediators of 
intercellular communication. These EVs, shed by a donor cell, are specifically equipped to 
mediate this communication since they contain proteins as well as mRNAs and miRNAs, 
which may be transferred to recipient cells. In particular, it has become evident that EVs 
may carry miRNAs that are responsible for drug resistance, from resistant to sensitive 
cells. However, it is not known if miR-21 (involved in drug resistance) is transported in 
EVs “shed” from chronic myeloid leukemia (CML) cells, and moreover if different types 
of EVs carry different levels of miR-21.  
Among the EVs, exosomes and microvesicles are the most described ones. In spite of the 
recent interest in the study of EVs, the technical problems associated with the isolation of 
pure populations of EVs hinder their classification, as well as the determination of their 
specific content. Therefore, the aim of this work was to extract EVs from K562 (CML) 
cells using four different protocols, in order to isolate different types of EVs. Furthermore, 
to analyse miR-21 expression levels in those different types of EVs. 
EVs were isolated from K562 cells with different isolation methods. Depending on the 
method of EVs’ isolation, different population size distributions were found. Analysis of 
miR-21 expression in the EVs isolated with different protocols showed no significant 
differences in the levels of this miRNA. In conclusion, even though it is important to 
characterize isolated EVs and to define isolation protocols as a central tool for the study of 
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Increasing interest is being given to the intercellular communication mediated by the 
transfer of extracellular vesicles (EVs) (Raposo and Stoorvogel 2013; Lee et al. 2012). 
Release of vesicles in several specific circumstances had been widely accepted, such as 
that the release of apoptotic bodies during apoptosis (Nunez et al. 2010). However, it was 
only recently shown that EVs were also shed from healthy cells, having been found in most 
bodily fluids (Andaloussi et al. 2013).Indeed, EVs have emerged not only as playing 
important roles in physiological processes but particularly as being associated with several 
diseases, including cancer  (Muralidharan-Chari et al. 2010; Jorfi and Inal 2013; Azmi et 
al. 2013). 
According to their biogenesis, EVs are often classified into three main classes: exosomes, 
microvesicles and apoptotic bodies. All of them are cell-derived vesicles, enclosed by a 
lipid bilayer with sizes ranging from 30 nm to 2000 nm in diameter, depending on their 
origin. While apoptotic bodies (sized 500-2000 nm) are originated from disintegrating 
dying cells, microvesicles (sized 50-1000 nm) are generated by budding from the plasma 
membrane and exosomes (sized 30-120 nm) are derived from the endolysosomal pathway 
(Andaloussi et al. 2013). However, there is still lack of knowledge of the exact molecular 
mechanisms which are responsible for their formation. In addition, the isolation of pure 
populations (consisting of only one type of EVs), from the heterogeneous populations with 
overlapping size distributions is still technically demanding (with the isolation methods 
available to date), which hampers not only their proper identification but also the 
understanding of which molecules are specifically or “packaged” in the different EVs 
(Guduric-Fuchs et al. 2012; Gyorgy et al. 2011).  
Nevertheless, several molecules have been described as being enclosed into EVs, such as 
lipids, proteins or mRNAs (Andaloussi et al. 2013; Raposo and Stoorvogel 2013). In 
addition, microRNAs (miRNAs), which are small RNA molecules that regulate gene 
expression through the binding to target mRNAs, thereby causing their degradation or 
inhibition of translation (Filipowicz et al. 2008; Valencia-Sanchez et al. 2006), have also 
been described as being transferred between cells via EVs (Valadi et al. 2007; Umezu et al. 
2013). miRNAs are known to regulate several important cellular processes. Alterations in 
miRNA’s expression are associated with several diseases, including cancer (Iorio and 




Croce 2012; Farazi et al. 2013). Moreover, miRNAs deregulation has been shown to be 
implicated in tumor cellular response to chemotherapy (Allen and Weiss 2010; Giovannetti 
et al. 2012). Importantly, some miRNAs are possibly being selectively packaged into EVs 
(Chen et al. 2012). This may account for the fact that the “EVs cargo” may not reflect the 
miRNA profiles of the donor cells (Valadi et al. 2007; Skog et al. 2008; Mittelbrunn et al. 
2011) and also for the existence of a cellular selection mechanism through which miRNAs 
are either retained or transferred between cells (Collino et al. 2010; Ohshima et al. 2010; 
Pigati et al. 2010). 
One miRNA in particular, oncomiR-21 has already been described in EVs (Zhou et al. 
2013). This miRNA is found overexpressed in almost all tumors (Volinia et al. 2006) and 
its involvement in chemoresistance has been addressed in various cancers. OncomiR-21 
has been described in microvesicles from glioblastoma (Skog et al. 2008) and its levels 
were found to be higher in serum microvesicles from glioblastoma patients than in healthy 
controls (Skog et al. 2008).  In addition, exosomal miR-21 expression was found to be up-
regulated in serum from patients with esophageal squamous cell cancer when compared to 
serum from patients who have benign diseases without systemic inflammation. In that 
study, the presence of miR-21 in exosomes positively correlated with tumor progression 
and aggressiveness (Tanaka et al. 2013). 
The aim of the present study was to extract EVs from K562 (CML) cells using four 
different protocols, in order to isolate different types of EVs. Furthermore, to analyse miR-








Materials and methods 
 
Cell culture  
Chronic myeloid leukemia cell line K562 (ECACC, European Collection of Cell Cultures, 
UK) and its derived cell line K562Dox (a kind gift from Professor J. P. Marie, Paris, 
France) were cultured in RPMI 1640 with Ultraglutamine I medium (Lonza) with 10% 
fetal bovine serum (FBS, PAA). Cells were maintained at 37 ºC in a humidified 
atmosphere containing 5% CO2. Cellular viability and concentration were determined by 
the Trypan Blue exclusion assay.  
 
EVs isolation by Differential Centrifugation 
Confluent cells (8-10x105 cells/ml), growing in the previous described medium (35ml) 
were centrifuged at 500 g for 5 min to pellet whole cells. The supernatant was then 
centrifuged at 15000 g for 1 h at 15 ºC to pellet the vesicles. The final pellet was 
resuspended in HBSS buffer (Sigma-Aldrich) and centrifuged at 2000 g for 2 min to 
remove debris. The clear vesicles suspension was further centrifuged at 18000 g for 30 min 
at 15 °C to pellet the vesicles.   
 
EVs isolation with ‘ExoQuick-TC’ from Systems Biosciences 
Confluent cells (9x105 cells), growing in the previous described medium were centrifuged 
at 3000 g for 15 min to remove cells and debris. The supernatant was then transferred to a 
new eppendorf and 150 μl of ExoQuick-TC Exosome precipitation solution were added to 
this cell-free culture media. The culture media/precipitation solution mixture were then 
incubated at 4 °C overnight and centrifuged at 1500 g for 30 min to pellet the vesicles.  
 
EVs isolation with ‘Total Exosome Isolation kit’ from Invitrogen 
Confluent cells (9x105 cells), growing in the previous described medium were centrifuged 
at 2000 g for 30 min to remove cells and debris. The supernatant was transferred to a new 
eppendorf and 500 μl of Total Exosome Isolation reagent were added to the cell-free 
culture media. The culture media/reagent mixture were then incubated at 4 °C overnight 
and centrifuged at 10.000 g for 1h at 4 °C to pellet the vesicles. The pellet was resuspended 
in the appropriate buffer. 
 
 




EVs isolation by Ultracentrifugation 
Confluent cells, growing in the previous described medium (10 ml) were centrifuged at 
300 g for 10 min to pellet cells. Supernatant was then centrifuged at 2000 g for 10 min at 4 
ºC to pellet debris. Supernatant was further centrifuged at 10.000 g for 30 min at 4 ºC to 
remove larger vesicles and apoptotic bodies. The clear supernatant was finally centrifuged 
at 100.000 g for 70 min at 4 °C to pellet the vesicles. Lastly, the vesicles were washed with 
PBS 1x and re-centrifuged at 100.000 g for 70 min at 4 °C.  
 
Dynamic light scattering (DLS) 
Extracellular vesicles were resuspended in PBS. Particle size (nm) and count rates (kilo 
cycles per second, kcps) were measured using a Nano series Malvern Zetasizer Instrument 
(Prager Instruments). The measurement duration was adjusted automatically with three 
measurements per sample. 
 
miRNA expression analysis 
Total RNA was extracted from cells or from the isolated vesicles using the miRvana 
miRNA isolation kit (Ambion) following the manufacturer’s instructions. Quantitative 
real-time PCR (qRT-PCR) was carried out with the miScript System (Qiagen) as 
previously described (Seca et al. 2013) using miR-21 primers form Qiagen (Hs_miR-
21_2). Serial dilutions of K562 cDNA were used for standard curve determination to 
assess PCR reaction efficiency. A dissociation curve was generated and a single peak 
obtained. Reactions from three independent experiments were run in duplicate or triplicate 
and negative control reactions without RT or template were included. 
 
  




Results and Discussion 
 
 
Comparison of protocols and analysis of the populations of EVs isolated with the 
different protocolss 
Several studies have shown that the term “EVs” may account for different types of 
“nanosized particles”. The technology available to date does still not allow the isolation 
and characterization of pure populations of EVs, having specific sizes. Therefore, in the 
present study four different protocols were compared regarding the isolation of EVs from 
the same cell line (K562): i) the commercially available ‘ExoQuick-TC’ (from System 
Biosciences);  ii) the ‘Total Exosome Isolation kit’ (from Life Technologies);  iii) a 
protocol based on  differential centrifugation (Jaiswal et al. 2012) and iv) a protocol based 
on ultracentrifugation (Thery et al. 2006).  
Table 1 presents a comparison between the different protocols, showing the advantages 
and disadvantages of each one. From this comparison, it is possible to see the used kits 
provided faster extractions of EVs, with lower amounts of cells required and higher 
amount of EVs recovered. On the other hand, both the centrifugation protocols required 
considerable longer times, bigger amounts of cells and provided lower amounts of EVs.  
The EVs isolated (from K562 cells) with the different protocols were analysed regarding 
their size distribution using DLS analysis (Figure 1). Some differences in the size profile of 
the populations of EVs isolated were clearly observed between some of the methods, 
although with the two commercially available kits similar sizes of EVs were obtained. 
Indeed, the size profiles of the EVs isolated with the ‘ExoQuick-TC’ and the ‘Total 
Exosome Isolation kit’ presented peaks around 35 nm. Since the results were very similar 
with the commercially kits, it was decided to the use ‘ExoQuick-TC’ for further 
comparisons, which from the two methods had the advantage of being a slightly faster 
protocol.  Therefore, when comparing the ‘ExoQuick-TC’ with the ultracentrifugation 
protocol, the results were also similar in terms of size population distribution, although a 
slender peak of EVs (indicative of more identical  vesicles) lower than 100 nm was 
observed with the ultracentrifugation protocol. On the other hand, differences were clearly 
observed when comparing these results with EVs isolated using the differential 
centrifugation protocol. Indeed, EVs isolated with this later method presented two peaks of 
sizes, a very small one (representing a small percentage of the EVs isolated) around 200 
nm and another one (representing the majority of EVs) around 800 nm. Analysing all the 




results it was possible to observe that the differential centrifugation protocol allowed the 
isolation of populations of EVs with bigger sizes than the remaining protocols. 
 
Analysis of the miR-21 levels in the isolated EVs 
 miR-21 is known to be overexpressed in various types of cancer (Volinia et al. 2006; Seca 
et al. 2013). Moreover, miR-21 has been found in EVs released from cancer cells (Skog et 
al. 2008; Tanaka et al. 2013). However these studies were carried out using the ‘ExoQuick-
TC’ or ultracentrifugation protocols only, which, as previously referred, isolate EVs with 
similar sizes. Therefore, in this study, we decided to analyse and compare the expression 
levels of miR-21 in EVs with different size ranges, by comparing miR-21 levels in EVs 
isolated with ‘ExoQuick-TC’ and differential centrifugation protocols. 
Analysis of miR-21 expression levels in the EVs may not be straightforward. One of the 
major difficulties is the choice of the appropriate internal control which allows the 
normalization of the experiments. Indeed, although cellular miRNAs expression levels are 
commonly normalized to the levels of a small nuclear RNA, U6 (Meyer et al. 2010), in the 
EVs context it is not possible to find proper controls. Examples of controls that have been 
used include: U6 alone (Ismail et al. 2013; Mocharla et al. 2013), U6 together with U1 (da 
Silveira et al. 2012), snoRNA U38B and snoRNA U43 (Hunter et al. 2008), or even a pool 
of the most stable miRNAs (Grange et al. 2011; Collino et al. 2010). However, U6 
expression has been shown to be unsuitable for normalization of serum miRNA levels 
(Benz et al. 2013) and the other mentioned controls may vary between different 
populations of EVs which makes them unreliable controls. Due to lack of appropriate 
“house-keeping” RNAs in the EVs, several studies of miRNA’s expression analysis have 
been carried out using the Ct-values, starting with equivalent amounts of total RNA, 
(Muller et al. 2011; Ogawa et al. 2010; Ng et al. 2013). Taking all this information into 
account, we have decided to analyse our results using the determined Ct-values (beginning 
all the experiments with equivalent amounts of total RNA). Results of the levels of miR-21 
in the populations of EVs extracted with the two protocols (‘ExoQuick-TC’ and 
differential centrifugation) showed the presence of this miRNA in both populations of EVs 
analysed. Moreover, even though the sizes of the two EV’s populations extracted with the 
different protocols were different, no significantly differences in the amount of miR-21 
were observed when comparing the two isolation protocols (Table 2),  




These results show that different protocols for EV’s isolation provide different EV’s 
populations but that in spite of these differences, the expression of miR-21 does not vary 
between EVs, implying that its expression is common to different types of EVs. 
In conclusion, our study showed that different protocols take different times and require 
different amounts of cells to initiate the protocol.  In addition, different protocols may 
isolate EVs with different characteristics (sizes). Therefore, when analysing the existing 
literature it is important to clearly know which protocols were used.   Moreover, this study 
showed that miR-21 levels were not dependent on the type (size) of EVs isolated, 






























































































Table 1 – Comparison of various protocols for extracellular vesicles isolation from K562 cells. 
 
 
*outcome refers to the amount of EVs obtained. 
 
 





 ‘ExoQuick-TC’ protocol Differential centrifugation protocol 
miR-21 Ct 19.66 ± 0.12 21.93 ± 0.27 22.51 ± 0.39 
































35 ml ____ . Only requires centrifugations 
. Time consuming 
. Huge sample 
volume 






1h + overnight 
incubation + 
48h to grow 
confluent cells 
1 ml 150 μl 
. Easy to perform 
. Small sample 
volume 
. High outcome 
 









48h to grow 
confluent cells 
1 ml 500 μl 
. Easy to perform 
. Small sample 
volume 
. High outcome 
 
. Commercial kit cost 
Ultra-
centrifugation 4h 




10 ml ____ . Only requires centrifugations 
 
. Time consuming 
. Moderate sample 
volume 
. Moderate outcome 
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miR-128 has been associated with cancer, namely with leukemia. In particular, this miR 
has been described, together with other miRs, to allow the discrimination between AML 
(acute myeloid leukemia) and ALL (acute lymphoblastic leukemia). In addition, miR-128 
is included in miR signatures which not only allow characterizing a particular subtype of 
AML but that are also associated with worse clinical outcome in a subgroup of patients 
with high-risk molecular features of AML. Nevertheless, all the published studies are 
based on data from expression arrays and no functional studies have been performed. 
Therefore, in order to further understand the role of miR-128 in AML cells and in their 
response to some chemotherapy, overexpression of miR-128 was achieved with miR-
mimics in an AML cell line (HL-60). This resulted in decreased cellular viability and 
increased sensitization to both etoposide and doxorubicin. Overexpression of miR-128 
increased programmed cell death but had no effect on cell cycle profile, apoptosis or 
autophagy,  as  no alterations were observed in the protein levels of PARP, pro-caspase-3, 
Vps34, Beclin-1 or LC3-II. In addition, miR-128 overexpression increased in the levels of 
DNA damage, as could be concluded by an increase in the comet’s tail intensity in the 
comet assay, an increase in the number of DNA repair foci stained with either γ-H2AX or 
53BP1 proteins, and an increase in the levels of these two proteins (observed by Western 
blot). To the best of our knowledge, this is the first association of miR-128 with DNA 











The aberrant expression of microRNAs (miRs) is associated with various diseases, 
including cancer where they can function as oncogenes or tumor suppressor genes [1-4]. 
miR-128 has been associated with cancer. This association was first suggested in 2005 
when, through miR microarrays analysis, miR-128 expression was found downregulated in 
glioblastoma tissue and cell lines [5]. Later, in 2007, a study was published which 
discriminated acute lymphoblastic leukemia (ALL) from acute myeloid leukemia (AML) 
through the analysis of their miR expression signatures [6]. In this study, miR-128 was one 
of the four miRs that could accurately distinguish these two types of leukemias being 
overexpressed in ALL, when compared to AML samples [6]. 
miR-128 was later found, in a microRNA signature that is associated with clinical 
outcome, to be associated with a subgroup of patients with high-risk molecular features of 
AML (those who have FLT3-ITD, wild-type NPM1, or both). miR-128 increased 
expression was associated with increased risk of incomplete remission, relapse or death 
[7]. 
miR-128 (which is a brain-enriched miR) is transcribed from two different gene copies 
located on chromosomes 2 and 3,  named miR-128-1 and miR-128-2, respectively. The 
resulting two miRs (both miR-128) are identical in their mature forms. 
A study by Weiss and collaborators was the first to describe a direct target for miR-128 
[8]. In this study, downregulation of EGFR was shown to occur through miR-128 direct 
interaction. In addition, this work showed that in lung cancer cell lines and also in clinical 
specimens, mir-128 deletion had a significant correlation with positive patient response 
and survival to EGFR tyrosine kinase inhibitor treatment with gefitinib [8]. 




Since then, other targets for this miR have been described. In neuroblastoma cells, miR-
128 was shown to target and downregulate the expression of Reelin and DCX, two proteins 
involved in the migratory potential of neural cells [9]. In addition, the oncogene/stem cell 
renewal factor, Bmi-1, has also been described as a target of miR-128. In fact, miR-128 
was found to be downregulated in gliomas and its overexpression reduced glioma cell 
proliferation and self-renewal through Bmi-1 targeting [10].  
miR-128 was also shown to target E2F3a mRNA, preventing its translation and thus 
inhibiting the proliferation of glioma cells [11].  Low miR-128 expression may contribute 
to glioma and glioblastoma increase in proliferation by coordinately upregulating the 
described transcription regulators (Bmi-1 and E2F3a) as well as ARP5 (another of its 
described targets known to regulate cell regeneration and proliferation), resulting in 
uncontrolled proliferation of brain cells [12]. There are other studies that have also 
depicted Bmi-1 as one of the main targets of miR-128. In one of such studies, by 
increasing intracellular reactive oxygen species levels via inhibition of Bmi-1, miR-128 
inhibited cell growth by promoting senescence in medulloblastoma cancer cells [13]. In 
pituitary tumor cells, miR-128 was found to be downregulated when compared to normal 
tissue and confirmed (by luciferase assay) that miR-128 targets Bmi-1, contributing to the 
involvement of miR-128 in the regulation of tumorigenicity and invasiveness. This 
regulation involved the binding of Bmi-1 to PTEN promoter, decreasing PTEN expression 
levels and leading to an increase in AKT activity in the pituitary tumor cells [14]. 
Ectopic expression of miR-128 in breast tumour-initiating cells (BT-ICs) led to a decrease 
in cell viability, increase in apoptosis and in DNA damage upon further treatment with 
Doxorubicin. In this study, miR-128 directly decreased the mRNA translation not only of 
Bmi-1 but also of ABCC5 (multidrug resistance-associated protein 5 involved in the export 
of xenobiotics from the cell). The same authors also found that patients with high miR-128 




expression have significantly longer overall survival, after being submitted to 
chemotherapy, than those with low miR-128 expression [15]. 
Apoptosis related proteins have also been described as being (direct or indirect) targets of 
this miR. miR-128 was found to bind Bax mRNA, leading to its decreased translation in 
human embryonic kidney cells and breast cancer cells [16, 17], and to indirectly increase 
Bcl-2 expression in neuroblastoma cells [18]. miR-128 was also shown to induce apoptosis 
via PUMA upregulation, by interfering with SIRT1 expression in breast and colon cancer 
cells  [19]. 
miR-128 has also been suggested to target the TGFβ signaling pathway [20]. Indeed, it was 
shown to decrease TGFβRI protein expression by binding to the 3’UTR region of its 
mRNA in breast cancer cells [20]. In gliomas, miR-128 has also been shown to inhibit 
tumor growth and angiogenesis by directly targeting p70S6K1 (a key downstream target of 
mTOR pathway) and its signaling molecules (namely HIF-1α and VEGF) [21].  
miR-128 was suggested as a tumor suppressor miR that is globally found  downregulated 
in human glioma, exerting a tumor suppressive function by increasing cell cycle arrest and 
increasing apoptosis. miR-128 also represses glioma-initiating neural stem cells growth, 
enhancing neuronal differentiation by directly targeting two oncogenic receptor tyrosine 
kinases - the epithelial growth factor receptor (EGFR) and the platelet-derived growth 
factor receptor-α (PDGFR-α) [22]. 
In prostate, miR-128 levels were elevated in benign epithelial cell lines compared with 
invasive cancer cells and silencing of miR-128 induced invasion in the benign epithelial 
cells, whereas its overexpression attenuated invasion in cancer cells [23]. 
miR-128 was also shown to target and downregulate the colony stimulating factor-1 (CSF-
1) mRNA and protein expression in ovarian cancer cell lines leading to their decreased cell 
motility and adhesion [24]. 




Very recently miR-128 was described to belong to a group of miRs which target the RET 
proto-oncogene in acute leukemia [25]. 
Interestingly, treatment with some drugs/natural products has been shown to increase miR-
128 levels. Indeed, NVP-LDE-225, a drug in early-stage clinical trials, increased miR-128 
expression therefore inhibiting Bmi-1 and thus regulating stemness and cancer stem cell 
growth [26]. Also in glioma, miR-128 was found to be upregulated upon treatment with the 
ginsenoside Rh2, a component of the traditional medicinal plant ginseng, mediating a Rh2 
anti-proliferative effect [27]. 
 AML is a clonal disorder of hematopoietic stem cells characterized by a rapid growth of 
abnormal white blood cells that accumulate in the bone marrow and interfere with the 
production of normal blood cells. The neoplastic myeloblasts are “frozen” at various stages 
of incomplete maturation, with a loss in the normal hematopoietic function due to 
alterations in the mechanisms of self-renewal, proliferation and differentiation [28-30]. 
Several reports have associated miR-128 and leukemia [6, 7, 25, 31, 32].These reports 
have shown that miR-128 belongs to a set of miRs that can distinguish between AML and 
ALL (acute lymphoblastic leukemia) [6, 31]. Moreover, that a particular subtype of AML 
with the translocation t(8;16)(p11;p13) may be characterized by a distinctive miR signature 
that includes miR-128 [25] or that miR-128 is part of a miR signature that is associated 
with worse clinical outcome in a subgroup of patients with high-risk molecular features of 
AML [7]. Nevertheless, all these studies were based on expression arrays and in none of 
them functional studies have been carried out nor analysed miR-128 expression regarding 
therapy response, in order to understand the role of miR-128 in leukemia cells. Therefore, 
to further understand the effect of miR-128 in acute myeloid leukemia, the overexpression 
of miR-128 in an AML cell line (HL-60) was performed with miR-mimics. In addition, the 
effects of this overexpression on DNA damage and in drug sensitivity were analysed. 




Material and Methods 
Human samples 
A total of 13 human normal blood and 11 bone marrow AML samples were obtained from 
Centro Hospitalar São João, Porto, Portugal. The study was approved by the São João 
Hospital's ethical review board and it was designed according the tenets of the Declaration 
of Helsinki. Written informed consent was obtained from all participants. Samples were 
separated using Ficoll-Paque PLUS (GE Healthcare). Briefly, samples were mixed with 
sterile PBS, placed on Ficoll-Paque PLUS and centrifuged for 30 min at 400g. White blood 
cells were harvested and washed in PBS before freezing at -80ºC. RNA was then extracted 
and analysed following the protocol mentioned below in “microRNA-128 expression 
analysis” of this section. 
 
Cell line 
HL-60 (acute myeloid leukemia) cell line, purchased  from DSMZ, was genotyped and 
maintained in RPMI 1640 medium with ultraglutamine I (Lonza) supplemented with 10% 
fetal bovine serum (FBS, PAA Laboratories) at 37ºC in a humidified atmosphere 
containing 5% CO2 in air. Cellular density and viability were routinely analysed with 
Trypan Blue exclusion assay.  
 
Transfection of HL-60 cells with pre-miR-128 
HL-60 cells (5x105 cells/mL) were transfected with the following pre-miRs from Life 
Technologies: pre-miRNA for miR-128 (miR-128) and negative control Pre-miR™ 
miRNA Precursor Molecules Negative Control #1 (miR-NC). For transfection, 
Lipofectamine™ and Plus™ reagents (Life Technologies) were used following 
manufacturer’s instructions. All transfections were performed in serum free medium for 




the initial 3 h using 50 nM of pre-miRs. FBS was then added to achieve a final 
concentration of 10%. Cells were further incubated or processed according to the following 
protocols. 
 
Treatments with Doxorubicin and Etoposide 
Following 3 h of transfection (as described above), doxorubicin (30 nM) or etoposide (200 
nM) were added to the cells. The equivalent volume of the drug vehicle (DMSO) was 
added to control cells. Cell number and viability were determined 24 and 48 h later, with 
the Trypan Blue exclusion assay. 
 
miR-128 expression analysis 
Total RNA was extracted from human samples and from HL-60 cells (24 h following 
transfection of pre-miRs), using TRI Reagent® (Life Technologies) following the 
manufacturer’s instructions, except for the use of chloroform instead of 1-bromo-3-
chloropropane as previously described [33]. Quantitative real-time PCR (qPCR) was 
carried out with the miScript SYBR Green System (Qiagen), as previously described [33] 
using the following primers from Qiagen: miR-128 (Hs_miR-128_1) and U6 
(Hs_RNAU6B_2, as control). For each primer, serial dilutions of HL-60 cDNA were used 
for the standard curve determination. A dissociation curve was generated and a single peak 
obtained. Reactions from three independent experiments were run in duplicate and 
negative control reactions without RT or template were included. PCRs were performed in 
7500 Fast Real-Time PCR System (Applied Biosystems) and results analysed with 7500 
Software v2.0.6 (Applied Biosystems). 
 
 




Expression of proteins involved in apoptosis, autophagy and DNA damage – Western blot 
Following 24 or 48 h transfection with pre-miRs, cell protein lysates were prepared, 
quantified and protein expression analysis was performed by Western blot, as previously 
described [34, 35]. The following primary antibodies were used: Beclin-1 (1:1000), LC3 
(1:1000) and Vps34 (1:1000) from Cell Signaling; PARP (1:2000), 53BP1 (1:400), p-
Histone H2A.X (Ser 139) (1:200) and Actin (1:2000) from Santa Cruz Biotechnology, Inc., 
and caspase-3 (1:2000) from Millipore. The secondary antibodies used were: anti-mouse 
IgG–HRP (1:2000); anti-rabbit IgG-HRP (1:2000); anti-goat IgG-HRP (1:2000), from 
Santa Cruz Biotechnology, Inc. 
 
Analysis of programmed cell death and apoptosis 
Programmed cell death was assessed with TUNEL assay using the “in situ cell death 
detection kit” (Roche), as previously described [36], 24 and 48 h following transfection 
with pre-miRs. Briefly, cells were fixed in 4% paraformaldehyde (PFA) and cytospins 
prepared. Cells were permeabilized in ice-cold 0.1% Triton X-100 in 0.1% sodium citrate 
and incubated with TUNEL reaction mixture (enzyme dilution 1:20). Slides were mounted 
in Vectashield Mounting Media with DAPI and observed in a DM2000 fluorescence 
microscope (LEICA). A minimum of 300 cells per slide were counted for a semi-
quantitative evaluation of cells undergoing programmed cell death.  
Apoptosis was quantified 48 h following transfection with pre-miRs by flow cytometry 
using the Annexin V-FITC/PI apoptosis Kit (Bender MedSystems) according to the 
manufacturer’s instructions as previously described [37]. Flow cytometry analysis of 
phosphatidylserine externalization was carried out using an Epics XL-MCL Coulter flow 
cytometer plotting at least 20,000 events per sample and the FlowJo 7.6.5 software (Tree 
Star, Inc.). 




Analysis of cellular proliferation and cell cycle profile 
Cellular proliferation was analysed using the BrdU incorporation assay. Briefly, 47 h 
following transfection with pre-miRs, cells were subjected to a pulse of BrdU (10 M) for 
1 h and then fixed in 4% PFA in PBS as previously described [38]. Cytopsins were 
prepared and slides incubated with 2 M HCl for 20 min. Cells were incubated with mouse 
anti-BrdU (1:10, Dako) for 1 h and further incubated with anti-mouse IgG-FITC (1:100, 
Dako). Slides were mounted in Vectashield Mounting Media with DAPI and cells 
observed in a DM2000 microscope (LEICA). A semi-quantitative evaluation was 
performed by counting a minimum of 500 cells per slide. 
For cell cycle profile analysis, cells were harvested and fixed in 70% ethanol and 
subsequently resuspended in PBS containing 0.1 mg/mL RNase A and 5 µg/mL propidium 
iodide, prior to analysis. The percentage of cells in the G1, S and G2/M phases of the cell 
cycle were determined using the FlowJo 7.6.5 software (Tree Star, Inc.) after cell debris 
and aggregates exclusion [39] and plotting at least 10000 events per sample.  
 
Analysis of DNA damage by the alkaline- Comet assay 
Cells were harvested 24 and 48 h of after transfection and frozen (in 10% DMSO in FBS) 
at -80 ºC. After thawing, cells were washed in PBS, resuspended in 0.6% low melting point 
agarose and quickly poured onto slides, precoated with 1% agarose in water, with the aid 
of a coverslip. Slides were kept on ice for 10 min to allow agarose to set. After removing 
the coverslip cells were lysed with ice-cold lysis buffer (100mM Na2EDTA, 2.5M NaCl, 
10mM Tris-HCl, pH 10.0, 1% Triton X-100) overnight, in the dark, at 4 ºC, followed by 
two 10 min washes in ice-cold distilled water. Slides were transferred to the 
electrophoresis tank filled with electrophoresis buffer (10 M NaOH; 200mM Na2EDTA) 
and incubated for 20 min to allow DNA unwinding. Samples were subjected to 




electrophoresis, for 20 min at 23 V, 300 mA. Slides were then flooded with neutralisation 
buffer (0.4 M Tris, pH 7.5) for 20 min and then rinsed in ice-cold water for 10 min before 
being allowed to dry at room temperature overnight. Slides were rehydrated with distilled 
water for 30 min before being flooded with 2.5 µg/mL of propidium iodide solution and 
incubated for 20 min at room temperature in the dark. Propidium iodide was rinsed with 
distilled water for 30 min and slides dried at 37 ºC. Comets were visualized using a LEICA 
DM2000 fluorescent microscope and analysed using the ‘Comet Assay IV v4.3’ imaging 
system (Perceptive Instruments). A minimum of 100 cells per condition were analysed. 
 
Expression of proteins involved in DNA damage – immunofluorescence 
To visualize 53BP1 and γ-H2AX protein expression, 24 and 48 h after transfection with 
pre-miRs, cells were fixed in 4% PFA and, after cytospin, incubated for 10 min in 50 mM 
of ammonium chloride in PBS. Cells were then permeabilized in ice-cold 0.2% Triton X-
100 in PBS for 10 min. After blocking with 2% BSA in PBS for 20 min, slides were 
incubated with a mouse antibody for phospho-Histone H2A.X (Ser139; 1:400 from 
Millipore) or a rabbit antibody for 53BP1 (1:200, from Santa Cruz Biotechnology) diluted 
in 2% BSA in PBS, overnight at 4º C. Cells were then washed with 2% BSA in PBS and 
incubated with an appropriate secondary antibody (mouse or rabbit IgG conjugated to 
FITC; 1:100; Dako) for 1 h at room temperature. Slides were mounted in Vectashield 
Mounting Media with DAPI (Vector Laboratories) and cells visualized using a 
fluorescence microscope ZEISS Axio Imager.Z1 coupled with ApoTome Imaging System 
microscope. Images were exported in TIF format, decompressed with Irfanview (ver. 4.35, 
Irfan Skiljan) and analysed with ImageJ (version 1.46r, 
http://rsbweb.nih.gov/ij/index.html), using a module written by Dr. Niklas Schultz at GMT 
Department, Stockholm University, Sweden [40]. This program evaluates the DAPI and 




FITC channels independently, identifies cell nuclei and registers foci parameters within the 
nuclear area. Foci area, intensity and the number of foci per nucleus were given in the 
software output file. 
 
Statistical analysis 
All data was statistically analysed with the two-tailed paired Student's t-test. Data was 




miR-128 overexpression in HL-60 cells decreases cellular viability and increases cellular 
sensitivity to doxorubicin and etoposide 
In order to understand the effect of miR-128 in an AML cell line, HL-60 cells were 
transiently transfected with miR-128 or with a control miR (miR-NC). Upon 24 h of 
transfection, a clear overexpression of miR-128 was detected, by qPCR, confirming the 
success of the transfection. Indeed, an average of 1480 times more miR-128 was observed 
in the miR-128 transfected cells in relation to cells transfected with miR-NC (Figure 1A). 
The effect of miR-128 overexpression on HL-60 cells was then assessed by analysing cell 
viable number. It was possible to observe that miR-128 overexpression decreased HL-60 
viable cell number to 92.0%, 84.3% and 81.0%, at 12 h, 24 h and 48 h after transfection 
respectively, when comparing to Blank cells (untreated cells in exponential growth). 
Moreover, this decrease was found to be statistically significant at 24 h and 48 h but not at 
12 h after transfection (Figure 1B). In addition, a very small decrease in viable cell number 
was observed in the miR-NC transfected cells but this decrease was not statistically 
significant. 




To confirm if miR-128 overexpression affected the HL-60 cells response to drugs, cells 
were treated with two chemotherapeutic drugs (doxorubicin and etoposide) following 
transfection with miR-128 or miR-NC, and the viable cell number was assessed.  As 
previously observed, miR-128 overexpression was found to decrease the viable cell 
number per se (white columns, Figure 1C). In addition, treatment with the drug vehicle 
(DMSO) did not affect viable cell number (grey columns, Figure 1C). Interestingly, miR-
128 overexpression sensitized HL-60 cells to doxorubicin, since a decrease in viable cell 
number was observed in cells transfected with miR-128 when compared with cells 
transfected with miR-NC. This sensitization was statistically significant at 24 h (striped 
columns, Figure 1C). miR-128 overexpression also sensitized HL-60 cells to etoposide as a 
decrease in viable cell number was also observed in cells transfected with miR-128 when 
compared with cells transfected with miR-NC. This sensitization was statistically 
significant at both 24 h and 48 h (checkered columns, Figure 1C). 
 
miR-128 overexpression does not affect cell cycle, cellular proliferation, apoptosis nor the 
expression of apoptosis-related and autophagy-related proteins  
Since miR-128 overexpression was found to significantly decrease HL-60 viable cell 
number and to sensitize these cells to the effect of the conventional chemotherapeutic 
drugs, etoposide and doxorubicin, we investigated some of the possible mechanisms 
involved. Hence, the effects of miR-128 overexpression on cell cycle profile, cellular 
proliferation, programmed cell death, apoptosis and autophagy induction were studied. 
Cells overexpressing miR-128 showed no alterations in cell cycle profile, analysed by PI 
staining and flow cytometry, both 24 h and 48 h following transfection (Figure 2A). The 
levels of BrdU incorporation in cells overexpressing miR-128 were also not altered, in 
relation to blank or miR-NC transfected cells (data not shown). On the other hand, when 




analysing programmed cell death (with TUNEL assay), an increase in the number of 
TUNEL labeled cells was observed following miR-128 overexpression, both at 24 h and 48 
h. This increase was statistically significant at 48 h following transfection (p<0.05), when 
comparing to cells transfected with miR-NC. Indeed, cells transfected with miR-128 
presented 8.2% TUNEL labeled cells, whereas cells transfected with miR-NC presented 
3.4% of (Figure 2B). Taking these results into account and since TUNEL may not only 
label apoptotic cells, a specific assay for apoptosis was carried out by analysing Annexin-
V/PI staining by flow cytometry. Surprisingly, when analysing the levels of apoptosis 
using this methodology, no major differences between cells transfected with miR-NC and 
cells overexpressing miR-128 were observed (Figure 2C). In addition, the expression 
levels of some apoptotic related proteins, namely procaspase-3 and PARP were also 
analysed by Western Blot and no significant alterations in their levels were observed 
between cells transfected with miR-NC and miR-128 (Figure 2D). Therefore, since 
autophagy has also been described as being involved in cell death, the expression of 
autophagy related proteins was analysed by Western Blot. Nevertheless, the levels of 
Vps34, Beclin-1 and LC3-II did not present any alterations between miR-NC and miR-128 
transfected cells (Figure 2E). 
 
miR-128 overexpression increases DNA damage 
In order to understand what was causing the decrease in viable cell number and increase in 
TUNEL labeling of miR-128 transfected cells, the effect of miR-128 overexpression in 
DNA damage induction was analysed by the comet assay and immunofluorescence for γ–
H2AX and 53BP1. By analysing the results from the comet assay, it was observed that the 
percentage of Comet Tail DNA (which is indicative of the % of DNA damage in that 
cell/comet) was higher in cells transfected with miR-128, than in cells transfected with 




miR-NC. This increase was from 3.6% in miR-NC transfected cells to 8.1% in miR-128 
transfected cells and was statistically significant (p<0.05) (Figure 3A). To further confirm 
that miR-128 overexpression induced DNA damage, DNA repair foci formation was 
analysed by immunofluorescence using antibodies for γ–H2AX and 53BP1. Moreover, the 
levels of both these proteins were analysed by Western blot. Results from the total number 
of γ–H2AX foci in cells (analysed by immunofluorescence) indicated that miR-128 
transfected cells presented a higher number of these foci per cell than cells transfected with 
miR-NC. This was observed both at 24 h and at 48 h following transfection, with this 
increase being statistically significant at 24 h for γ–H2AX (p<0.05) (Figure 3B). 
Accordingly, the levels of γ–H2AX were also increased in the Western blot analysis 24 h 
after miR-128 transfection (Figure 3C). Regarding 53BP1, cells overexpressing miR-128 
were also found to present a higher number of foci per cell, when compared with miR-NC 
transfected cells. This was also observed both at 24 h and 48 h, being statistically 
significant at 48 h (p<0.05) (Figure 3D). This increase was further confirmed by observing 
an increase in 53BP1 protein expression in miR-128 overexpressing cells (Figure 3E). 
 
miR-128 expression in AML patient samples 
Expression of miR-128 was analysed by qPCR in samples from PBMCs of 13 healthy 
donors and from bone marrow of 11 AML patients. Although the differences were not 
statistically significant, the expression levels of miR-128 in the AML samples were 1.87 










Over the last decade, the interest on miRs has grown tremendously with thousands of miRs 
being identified in various organisms [41]. miRs were shown to be crucial in regulating 
gene expression, mostly by post-transcriptional regulation, and controlling disease 
processes. Particularly, miRs have been described as being involved in cancer. Indeed, 
some miRs may act as ‘oncogenes’, whereas others act as ‘tumour suppressor genes’ [42]. 
Although miR-128 has been described as a brain-enriched miR [43] its expression has been 
shown to be altered in various types of cancer such as breast [17] or lung cancer [8]. 
Indeed, miR-128 has been shown to be involved in the regulation of important cell 
oncogenic processes such as cell proliferation [11], invasion [9] or apoptosis [19]. 
Moreover, miR-128 has been shown to be altered in leukemia [6, 7, 25, 31]. In this context, 
to date, there are no functional studies on miR-128 in leukemia cells. The present study 
adds knowledge to this area. 
In addition, drug resistance, which is frequently associated with poor prognosis in cancer 
[44, 45], has also been shown to be indirectly controlled by the expression of some miRs, 
as these molecules may regulate several cellular mechanisms that are pivotal for cancer 
drug resistance [46, 47]. Curiously, the involvement of miR-128 in drug resistance has 
been described in several studies, although some of them present contradictory results. On 
the one hand, some reports point out miR-128 expression as being related to sensitization 
to drugs [15], while others associate miR-128 expression with increased drug resistance 
[17, 48]. In order to clarify this issue, in the present study the effect of miR-128 on cellular 
sensitization to two chemotherapeutic drugs (doxorubicin and etoposide) was studied. 
Results from this work showed that overexpressing miR-128 per se decreased the viable 
cell number of HL-60 cells. This was in agreement with some of the previously published 
studies in different cancer cell models [11, 13, 21, 49]. In addition, in this study, miR-128 




overexpression was also shown to sensitize cells to the chemotherapeutic drugs - 
doxorubicin and etoposide. This was in agreement with other study in which miR-128 
overexpression sensitized breast tumor cells to doxorubicin [15]. Nevertheless, some other 
studies have shown the opposite effect in breast and lung cancer cells [17, 48]. In addition 
to this, the proliferation levels and cell cycle profile of HL-60 cells overexpressing miR-
128 showed no alterations, although alterations in both had been shown by others, for brain 
tumor cells and for human embryonic kidney cells [11, 12, 16]. These contradictory results 
may be explained by the different genetic background and tissue origin of the cell lines 
used in this study, compared to others.   
In this study, the fact that the percentage of TUNEL positive cells (suggesting programmed 
cell death) was increased in cells overexpressing miR-128 prompted us to further analyse 
the cellular levels of apoptosis. Nevertheless, when comparing miR-NC with miR-128 
transfected cells, no significant alterations were observed, neither in the Annexin-V/PI 
staining nor in the expression of the apoptosis related proteins procaspase-3 and PARP (the 
former, an enzyme known to be involved in the first steps of apoptosis and the latter, a 
recognized target of apoptosis induction). Nevertheless, the TUNEL assay has previously 
been described as not being specific for apoptosis, as it may also label non-apoptotic cells 
[50, 51]. In fact, there are studies showing that cells undergoing autophagy activation can 
also be labeled by TUNEL [52, 53]. This led us to analyse the expression of autophagy 
related proteins upon miR-128 overexpression. Nonetheless, also no alteration in 
autophagic protein levels was observed.  
Intrinsic DNA damage may arise from errors taking place during DNA replication, from 
endogenous reactive oxygen species (ROS) produced from normal metabolic byproducts or 
from extrinsic genotoxic stresses ( including ultraviolet light, ionizing radiation, chemo- 
and radiotherapeutic agents) [54, 55]. miR-128 has been predicted and shown to target 




proteins involved in DNA damage response [56-58] and interestingly, miR-128 has been 
recently shown to increase intracellular ROS levels [13].  The present study shows that 
miR-128 overexpressing leukemia cells had increased DNA damage. Indeed, results from 
the alkaline comet assay (a method that quantifies DNA damage by the increasing content 
of DNA in the tail of the comets) showed a clear increase in DNA tail intensity in miR-128 
overexpressing cells, as was already seen by others in breast tumor cells [15]. 
Confirmation of DNA damage induction was possible by monitoring γ–H2AX and 53BP1 
protein expression, whose foci are evidence of persistent DNA double strand breaks 
(DSBs) [59]. The observed increase in the number of foci of γ–H2AX and 53BP1 indicated 
an increase in DNA DSBs, which might justify the increased sensitivity to doxorubicin and 
etoposide of miR-128 overexpressing cells.  
Other miRs associated to DNA damage have been already described to interfere with 
chemosensitivity. For example, when miR-18a was overexpressed in colorectal cancer 
cells, those cells were less able to recover from etoposide-induced DNA damage when 
compared to cells transfected with a control miR, reflecting a compromised DNA DSBs 
repair mechanism [60]. Indeed, it is known that miR-18a reduces ataxia telangiectasia 
mutated protein, a central molecule in promoting repair of DNA DSBs [60]. 
In the context of AML, miR-128 may lead to DNA damage (possibly by affecting the 
expression of proteins involved in DNA repair, since as mentioned above, miR-128 has 
been shown to target proteins involved in DNA damage response [56-58]), that 
accumulates without prompt repair causing increased sensitivity to DNA damaging drugs 
such as etoposide and doxorubicin. 
Results from cell lines led us to analyse the levels of miR-128 in AML samples. A slight 
increase in the expression of miR-128 was found in AML bone marrow samples, when 
compared to PBMCs from healthy donors. Even though the differences were not 




statistically significant, this suggests that these patients may have an increased DNA 
damage. However, definitive conclusions cannot be taken from these results, as the sample 
size was very small. Nevertheless, further studies on the levels of DNA damage from these 
patients might help explaining the role of miR-128 in leukemia. In addition, it would be 
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Figure 1. Increasing miR-128 levels decreases HL-60 viable cell number and increases 
cellular sensitivity to doxorubicin and etoposide. (A) qRT-PCR analysis of miR-128 
levels, 24 h after transfection with miR-128 mimic or control miR (miR-NC). Results, 
expressed after normalization of the miR-128 values with the values obtained for U6, were 
analysed as % of the miR-NC transfected cells and represent the mean ± SE of six 
independent experiments performed in duplicate. (B) Viable cell number analysed 12 h, 24 
h and 48 h after transfection with miR-NC or miR-128. Results, presented as % of Blank 
cells, are the mean ± SE of four independent experiments. (C) Results are expressed as % 
of viable cell number in relation to Blank analysed 24 h and 48 h after transfection with the 
miR mimics (miR- 128 or miR-NC) and are the mean ± SE of three independent 
experiments. * p<0.05 miR-NC vs. miR-128. 
 
Figure 2. Increasing miR-128 levels on HL-60 cells does not affect cell cycle profile, 
apoptosis or expression of apoptosis and autophagy-related proteins. (A) Cell cycle 
profile analysed by flow cytometry. Results are represented as  % of cells in each phase of 
the cell cycle analysed 24 h and 48 h after transfection with the miR mimics (miR-128 or 
miR-NC) and are the mean ± SE of three independent experiments. (B) TUNEL assay. 
Results were analysed 24 h and 48 h following transfection with the miR mimics (miR-128 
or miR-NC) and are the mean ± SE of three independent experiments. *p<0.05 miR-NC vs. 
miR-128. (C) Levels of apoptosis analysed with Annexin V/PI staining by flow cytometry. 
Images are representative of three independent experiments. Western blot analysis of 
apoptosis-related proteins (D) and of autophagy-related proteins (E). Images are 
representative of three independent experiments. 
 




Figure 3. Increasing miR-128 levels increases DNA damage of HL60 cells. Cells were 
transfected with the miR-mimics (miR-128 or miR-NC) and analysed 24 h or 48 h 
following transfection. (A) Comet assay results analysed 48 h after transfection. 
Fluorescence Microscopy images of Comet Tail DNA are shown on the left of this panel. 
Arrows indicate DNA tails. Images are representative of a minimum of 100 cells (from two 
independent experiments). Quantification of the % of Tail DNA is shown on the right of 
this panel. (B) γ-H2AX foci analysed 24 h and 48 h after transfection. The left of the panel 
shows representative fluorescence microscopy photographs of γ-H2AX foci (from FITC 
labeling) and Dapi stained nuclei (blue) and are the mean ± SE of three independent 
experiments. Quantification of these foci is shown on the right of this panel. * p<0.05 miR-
NC vs. miR-128. (C) Western blot analysis of γ-H2AX protein.  Blot is representative of 
three independent experiments (left panel). Densitometry analysis of the Western blot for 
γ-H2AX (right panel). Results are expressed after normalization of the values obtained for 
γ-H2AX with the values obtained for actin, and also expressed as a % of the values 
obtained for blank. Results are the mean ± SE from 3 independent experiments. (D) 53BP1 
foci analysed 24 h and 48 h after transfection. The left of the panel shows representative 
fluorescence microscopy analysis of 53BP1 foci (green from FITC labeling) and Dapi 
stained nuclei (blue) and are the mean ± SE of three independent experiments. 
Quantification of these foci is shown on the right of this panel. * p<0.05 miR-NC vs. miR-
128. (E) Western blot analysis of 53BP1 protein.  Blot is representative of three 
independent experiments (left panel). Densitometry analysis of the Western blot for 53BP1 
(right panel). Results are expressed after normalization of the values obtained for 53BP1 
with the values obtained for actin, and also expressed as a % of the values obtained for 
blank. Each bar represents the mean ± SE from 3 independent experiments. * p<0.05 miR-
NC vs. miR-128. 
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 CHAPTER III.  
 




















A new layer of gene expression regulation has been introduced with the discovery of 
miRNAs. RNAs are no longer bystanders in gene expression and have become ‘first class’ 
intervenients, now known to control numerous cellular processes. Since their discovery in 
human cells (in 1993) miRNAs have been thoroughly studied and their relevance in cancer 
initiation, development and drug resistance has been well established. In leukemia, 
miRNAs have also been intensively studied, and various miRNA expression profiles have 
been performed, to characterize different subtypes of these malignancies as well as to 
stratify patients in terms of prognosis and response to therapy. Nonetheless, the cellular 
function of specific miRNAs which have been shown to have altered expression in 
leukemias has not been fully understood. 
 
Thus, driven by the will to add knowledge to this area, the aim of this work was to 
understand the cellular functions of two different miRNAs - miR-21 and miR-128 - known 
to be deregulated in CML and AML, respectively. For such, miRNA overexpression and 
downregulation approaches were used, and the resulting alteration in cellular mechanisms 
and response to chemotherapeutic drugs was studied. 
miR-21 is well known to be overexpressed in almost all types of cancers (Volinia et al. 
2006) including hematological malignancies (Jongen-Lavrencic et al. 2008). Its precursor 
and mature sequences are highly conserved across many species, suggesting a deeply 
conserved role for miR-21 in gene regulation (Selcuklu et al. 2009). In fact, its role as an 
oncomiR has also been well documented (Pan et al. 2010; Selcuklu et al. 2009).  
The updated hallmarks of cancer (Hanahan and Weinberg 2011) include sustaining 
proliferative signaling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, activating invasion and metastasis, 
reprogramming energy metabolism, and evading immune destruction. Moreover, genome 
instability and tumor-promoting inflammation are also considered two enabling 
characteristics of cancer (Hanahan and Weinberg 2011). By suppression of its function, 
miR-21 has been shown to be implicated in practically all of these mechanisms described 
by Hanahan and Weinberg (Buscaglia and Li 2011). Although it has a vast number of 
targets, miR-21 oncogenic function occurs predominantly by interfering with resistance to 
programmed cell death, particularly to apoptosis (Medina et al. 2010; Hatley et al. 2010). 
The findings presented in this thesis show that miR-21 may also participate in 
autophagy, contributing to chemoresistance of leukemia cells to anti-cancer drugs. Indeed, 
by decreasing miR-21 expression, we verified that Bcl-2 expression was decreased, in 
agreement with a previously reported study (Dong et al. 2011) . Besides its anti-apoptotic 
role, Bcl-2 is also an autophagy inhibitor by binding to Beclin-1. The present work shows 
that downregulation of Bcl-2 led to a decrease of the amount of this protein that was 




bound to Beclin-1, possibly allowing autophagy induction. Thus, this study reports a direct 
link between miR-21 targeting with antimiRs-21, its consequent decreased expression, and 
increased cellular autophagy. In another study, using malignant glioma cells, it was shown 
that decreasing miR-21 expression was associated with radio-sensitivity through enhanced 
autophagy, although miR-21 downregulation per se did not have any effect in autophagy 
(Gwak et al. 2012). These differences in the function of miR-21 by itself (without a drug 
“stimulus”) might be related to the different cell types used in the present study and in the 
one by Gwak et al. (2012). 
The present work also shows that autophagy is involved in cellular sensitization to the 
chemotherapeutic drugs doxorubicin and etoposide. Autophagy is a homeostatic 
mechanism for intracellular recycling and metabolic regulation and, at the same time, it is 
also stress responsive, since it is important for the removal of damaged proteins and 
organelles. In the cancer context, autophagy defects are associated with inflammation 
which may contribute to cancer formation (Mathew et al. 2007; White et al. 2010). 
Autophagy induction has been associated both with cancer progression and cancer 
inhibition, although the specific conditions determining whether autophagy boosts or 
inhibits cell death are not yet known. On some occasions, autophagy induces death 
(Ropolo et al. 2012; Gewirtz et al. 2009) and on other occasions, it plays a protective role 
rather than programming cell death (Ogier-Denis and Codogno 2003; Zou et al. 2012). 
Moreover, autophagy inhibition has been shown to augment the efficacy of anticancer 
agents in a variety of tumors (Degenhardt et al. 2006; Carew et al. 2007; Amaravadi et al. 
2007). However, autophagy induction has also been associated with increased drug 
sensitivity as shown by the present work and others (Pardo et al. 2010; Newman et al. 
2007). 
 
The conventional view of cell communication is that it is mediated through gradients 
of soluble ligands which are identified by the cell-associated receptors. However, recent 
studies demonstrated a novel form of inter-cellular communication, through the shedding 
of membrane vesicles by donor cells, which can fuse to and be internalized by acceptor 
cells in the surrounding area, the so called “neighboring cells” (Al-Nedawi et al. 2008; 
Skog et al. 2008). These extracellular vesicles (EVs) can contain proteins and RNAs, 
including mRNAs and miRNAs. The importance of the presence of miRNAs in EVs gained 
additional attention when secreted miRNAs were shown to exert their function in the 
recipient cells (Kosaka et al. 2010; Cantaluppi et al. 2012). In particular, miR-21 has been 
shown to be incorporated in EVs (Chen et al. 2012; Chiba et al. 2012).  
The term ‘EVs’ may account for different types of vesicles (from exosomes to 
microvesicles) and current available technology does not allow isolation of pure 




populations of these EVs. Therefore, in this thesis, four different protocols were compared 
regarding EVs’ isolation from K562 (CML) cells. The different isolation methods required 
different times to be executed and different amounts of cells to initiate the protocol. In 
addition, the different amounts of EVs recovered gave rise to different size population 
profiles. In particular, EVs isolated with the ‘ExoQuick-TC’ and the differential 
centrifugation protocols were the ones providing the most different population sizes. 
Nevertheless, even though the types (sizes) of the two EVs’ populations extracted were 
different, no significantly differences in miR-21 levels were observed when comparing 
these two isolation protocols (‘ExoQuick-TC’ and differential centrifugation), suggesting 
that miR-21 is not specifically “packaged” into a particular type of EVs. 
Given the fact that EVs are biocompatible, immunologically inert, can be patient-
derived if required, have an innate ability to cross major biological barriers including the 
blood–brain barrier (Alvarez-Erviti et al. 2011) and can carry miRNAs, it is also possible 
that they could be used as ‘drug’ vehicles for the delivery of exogenous miRNAs or 
antimiRs. In fact, some studies have already shown that EVs can mediate the transfer of 
exogenous nucleic acids (Zhang et al. 2010; Akao et al. 2011; Pan et al. 2012). 
Furthermore, combinatorial EVs‑based therapeutics will possibly be developed in the 
future. 
 
This work also shows that miR-128 overexpression increases the DNA damage 
observed in leukemia HL-60 cells, possibly explaining the increased chemosensitivity to 
doxorubicin and etoposide that these cells (with miR-128 overexpression) presented. 
However, the chemosensitizing role of miR-128 is not definitively established. Other 
works have shown the opposite effect for miR-128 overexpression (Donzelli et al. 2012). 
Even more puzzling is the contradictory effect of miR-128 expression in breast cancer cells 
when treated with the same drug - doxorubicin (Zhu et al. 2011; Ji et al. 2013), inferring 
that the genetic background of the cells must play an important role in the outcome.  
Once miRNAs are not known to directly cause DNA damage, it is supposed that miR-
128 is interfering with the DNA damage response (DDR) signaling network. The DDR is a 
signal transduction pathway that decides the cell’s fate to: i) repair the DNA damage, or  ii) 
undergo apoptosis if there is too much damage. The DDR network has classically been 
regarded as consisting of a kinase signaling cascade that leads to the inhibition of Cdk-
cyclin complexes and a delayed transcriptional response that promotes cell cycle arrest 
(Boucas et al. 2012). miRNAs act post-transcriptionally and are responsible for a third 
layer of DDR regulation. They have been shown to target and regulate the expression of 
several DDR intervenients (Han et al. 2012) and to be involved in (the initiation and 




progression of) tumorigenesis and also modulate the sensitivity of cells to DNA damaging 
agents (Wouters et al. 2011).  
DNA damage plays a dual role in cancer. On the one hand it causes mutations and/or 
chromosomal rearrangements, which may be the trigger for the carcinogenic process, and 
on the other hand it may be “used as  therapeutic approach” since many cytotoxic drug 
treatments rely on the use of DNA damaging agents, such as radiation, alkylating agents 
and DNA-crosslinking compounds, to induce cell death in cancer cells. In this context, 
further studies would be of great interest to clarify possible DDR targets of miR-128 in 
leukemic cells, which might be responsible for the increased DNA damage and increased 
sensitivity to chemotherapeutic drugs that was observed in this work. This would be of 
particular interest as it could be an additional strategy to overcome therapy resistance that 
is often associated with radio- and chemotherapy. 
In this work it was also shown that miR-128 expression in AML bone marrow samples 
was higher than in peripheral blood mononuclear cells. Although not statistically 
significant, these results suggest that these patients might have increased DNA damage 
and thus, might be more susceptible to cytotoxic agents. However, in order to be able to 
draw conclusions from these results, the sample size needs to be increased. At the same 
time, collecting post-treatment bone marrow samples from AML patients would also be 
very valuable, to confirm the hypothesis that these patients have increased susceptibility 
to cytotoxic agents. 
 
In this thesis, two different strategies have been employed to modulate miRNAs 
expression: miRNA antagonists and miRNA mimics. These techniques are being 
developed so that they can be introduced in the clinics as new therapeutic drugs. miRNA 
antagonists are used to inhibit miRNAs that are overexpressed in human diseases. These 
antagonists are conceptually similar to other inhibitory approaches, like siRNAs and 
antisense molecules. During the process of drug development, the miRNA that is being 
targeted can also be used as a biomarker for pharmacokinetic and pharmacodynamics 
optimization of the antagonist. miRNA inhibitors are usually single-stranded 
oligonucleotides, complementary to the targeted miRNA, with chemically modified 
backbones that allow increased half-life and affinity to the endogenous miRNA and the 
seizing of these miRNAs in a configuration that is unable to be processed by RISC. 
Therefore, miRNA inhibition occurs upstream of RISC and is presumably independently 
of cellular cofactors (Hutvagner et al. 2004; Meister et al. 2004; Orom et al. 2006). In 
contrast, miRNA mimics are used to restore the expression of miRNAs which show a 
cellular loss of function. This miRNA replacement allows the delivery of “therapeutic 
miRNAs” as short double-stranded oligonucleotides (Wiggins et al. 2010) that act 




downstream of RISC, thus requiring its enzymatic intervention. In this type of therapeutic 
approach the miRNAs would themselves be the ‘drug’, and the rationale for their 
development as therapeutics is that some of them present decreased expression in 
particular diseases. Their targets are irrelevant because the mimic carries the same 
sequence as the endogenous miRNA and is expected to regulate the same genes as in a 
‘non-disease’ situation. the therapeutic activity of miRNA antagonists and miRNA mimics 
could be monitored through the measurement of endogenous levels of the “targeted 
miRNA” but phenotypic assays which can capture all miRNA-induced changes to the 
transcriptome (such as genome wide mRNA expression analysis), would be the preferred 
method for the monitoring (Bader et al. 2011; Bader et al. 2010).  
Most clinical approaches such as the inhibition of some miRNAs (such as miR-10b, 
miR-21 or miR-451) or increasing the expression of other miRNAs (such as miR-16 or 
miR-34a) are currently only undergoing pre-clinical studies (Uchino et al. 2013). 
However, one miRNA antagonist is already undergoing clinical trials. Indeed, the miR-
122-specific antagonist, is currently undergoing Phase IIa clinical testing for patients 
infected with hepatitis C virus (Janssen et al. 2013). 
 
In spite of all these advances in miR-therapeutics, the main challenge for miRNAs 
ever becoming a ‘true’ therapy is the successful delivery of these molecules to the target 
tissue without compromising the integrity of the miRNAs (Davis et al. 2008; Castanotto 
and Rossi 2009; Whitehead et al. 2009). 
 
In conclusion, this work provided more insight into the role of miRNAs in leukemia, 
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